



Curriculum Vitae

Personal information **Ronald van Schaik**

Work experience

1. Employer: Utrecht University
 - Start date: 1987
 - End date: 1992
 - Position: PhD student
 - Activities: Setting up molecular biology at Dept. Biochemistry; characterization and cloning of phospholipase A2
 - Country: Netherlands
2. Employer: Academic Hospital Rotterdam
 - Start date: 1992
 - End date: 1996
 - Position: Post_Doc
 - Activities: Setting up molecular biology laboratory at the Dept Endocrinology and performing molecular biology research in oncology (germ cell tumors, prostate_, breast_ and ovarian cancer)
 - Country: Netherlands
3. Employer: Academic Hospital Rotterdam
 - Start date: 1996
 - End date: 1997
 - Position: Post_Doc
 - Activities: Development of molecular biological screening for colon cancer
 - Country: Netherlands
4. Employer: Academic Hospital Rotterdam
 - Start date: 1997
 - End date: 1999
 - Position: Post_Doc
 - Activities: Setting up molecular biology laboratory at the Dept Clinical Chemistry; performing molecular biology research in pharmacogenetics
 - Country: Netherlands
5. Employer: Erasmus MC
 - Start date: 2003
 - End date: 2013
 - Position: European Specialist Laboratory Medicine
 - Activities: Responsible for clinical chemistry testing on Pharmacogenetics, Cardiac Markers, Prostate Cancer, Kidney Stones and Point_of_Care Testing; Pharmacogenetic Research and Prostate Cancer Research
 - Country: Netherlands
6. Employer: Erasmus MC
 - Start date: 2013
 - End date:
 - Position: Full Professor Pharmacogenetics
 - Activities: Responsible for clinical chemistry testing on Pharmacogenetics, Cardiac Markers, Prostate Cancer; Pharmacogenetic Research and Prostate Cancer Research
 - Country: Netherlands
7. Employer: Erasmus MC
 - Start date: 2021
 - End date: present
 - Position: Head Dept. Clinical Chemistry
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: Utrecht University
 - Start date: 1981
 - End date: 1987
 - Qualification: (Bio)Chemistry
 - Organisation:
 - Country: Netherlands
2. Subject: Cold Spring Harbor Laboratories, NY
 - Start date: 1988
 - End date: 1989
 - Qualification: Molecular Biology
 - Organisation: Molecular Biology
 - Country: United States
3. Subject: Erasmus MC
 - Start date: 2008
 - End date: 2008
 - Qualification: NIHES
 - Organisation: Statistics
 - Country: Netherlands
4. Subject: Erasmus MC
 - Start date: 1993

- End date: 1993
 - Qualification: Summerschool Endocrinology & Immunology
 - Organisation: Dept. Endocrinology & Immunology, Erasmus MC
 - Country: Netherlands
5. Subject: ASCPT
- Start date: 2003
 - End date: 2003
 - Qualification: Clinical Pharmacology Curriculum Review Course
 - Organisation: ASCPT
 - Country: Netherlands
6. Subject: Erasmus MC
- Start date: 2010
 - End date: 2010
 - Qualification: Leadership Program
 - Organisation: Management Erasmus MC
 - Country: Netherlands
7. Subject: Erasmus MC
- Start date: 2012
 - End date: 2012
 - Qualification: Teach-the-Teacher I
 - Organisation: Erasmus MC
 - Country: Netherlands
8. Subject: Erasmus MC
- Start date: 2021
 - End date: 2021
 - Qualification: Teach-the-Teacher III
 - Organisation: Erasmus MC
 - Country: Netherlands
9. Subject: EVBHC
- Start date: 2024
 - End date: 2024
 - Qualification: Value Based Health Care
 - Organisation: Erasmus MC
 - Country: Netherlands
- 10.

Additional information

Publications

1. Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome. van den Broek WWA, Azzahafi J, Chan Pin Yin DRPP, van der Sangen NMR, Sivanesan S, Dijkstra LM, Walhout RJ, Tjon Joe Gin M, Breet NJ, Langerveld J, Vlachoianis GJ, van Bommel RJ, Appelman Y, van Schaik RHN, Henriques JPS, Kikkert WJ, Ten Berg JM. *Eur Heart J Cardiovasc Pharmacother.* 2025 May 2;11(3):230-240. doi: 10.1093/ehjcvp/pvae087.PMID: 39537191 Free PMC article.
2. Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study. Heersche N, Lanser DAC, Oomen-de Hoop E, Içli A, de Bruijn P, Paats MS, van Rossum EFC, Koolen SLW, van Schaik RHN, Dingemans AC, Veerman GDM, Mathijssen RHJ. *Cancer Commun (Lond).* 2025 May 1. doi: 10.1002/cac2.70030. Online ahead of print.PMID: 40308149 No abstract available.
3. Genotype-Guided Asthma Treatment Reduces Exacerbations in Children: Meta-Analysis of Two Randomized Control Trials. Slob EMA, Vijverberg SJH, Ruffles T, Noij LCE, Biermann J, Brouwer AFJ, van den Brink K, de Bruin-Kok A, Van Ewijk BE, Haarman E, Hammer SC, Hashimoto S, Hogarth F, Jones CJ, Kamps AWA, Kersten ETG, de Kleer I, Lipworth BJ, Littleford R, Mérelle M, Moeller A, Palmer CNA, Pilvinyte K, Rutjes NW, van Schaik RHN, Smith HE, Tavendale R, Terheggen-Lagro SWJ, Turner S, Twisk JWR, Vaessen-Verberne A, Vervaal M, de Vries T, Wesseling J, Pijnenburg MW, Koppelman GH, Mukhopadhyay S, Maitland-van der Zee AH. *Allergy.* 2025 Apr;80(4):1006-1014. doi: 10.1111/all.16438. Epub 2024 Dec 26.PMID: 39723595 Free PMC article.
4. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonyleureas. Wolthuis DFGJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Risselada A, Rongen GAPJM, van Schaik RHN, Swen JJ, Touw DJ, van Westrhenen R, Deneer VHM, Houwink EJF. *Eur J Hum Genet.* 2025 Apr;33(4):413-420. doi: 10.1038/s41431-024-01769-7. Epub 2024 Dec 15.PMID: 39676086 Review.
5. Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC. Heersche N, Lanser DAC, Muntinghe-Wagenaar MB, Mohmaed Ali MI, Ulas EB, Trooster TMA, de Jonge E, Oomen-de Hoop E, Paats MS, Bahce I, Croes S, Hendriks LEL, van der Wekken AJ, Dingemans AC, Huitema ADR, van Schaik RHN, Mathijssen RHJ, Veerman GDM. *J Thorac Oncol.* 2025 Apr;20(4):475-486. doi: 10.1016/j.jtho.2024.11.025. Epub 2024 Nov 29.PMID: 39617342 Free article.
6. Pharmacokinetics of betamethasone in pre-eclampsia: An in vivo and ex vivo study. Schoenmakers S, Li L, Kluijvers ACM, Broekhuizen M, Harhangi MS, Danser AHJ, Reiss I, Allegaert K, van den Berg SAA, van Zelst BD, van Schaik RHN, DeKoning PLJ, Ronde E, Sassen SDT, Simons SHP, Koch BCP. *Br J Clin Pharmacol.* 2025 Mar 13. doi: 10.1002/bcp.70035. Online ahead of print.PMID: 40083164
7. Implementation of model-informed precision dosing for tamoxifen therapy in patients with breast cancer: A prospective intervention study. van Nijnatten RYM, Buijs SM, Agema BC, Fischer RMJ, Moghaddam-Helmantel IG, Contant CME, de Jongh FE, Huijben AMT, Kop M, van der Padt-Pruijsten A, Zuetenhorst HJM, van Schaik RHN, Koch BCP, Jager A, Koolen SLW, Mathijssen RHJ. *Breast.* 2025 Feb;79:103880. doi: 10.1016/j.breast.2025.103880. Epub 2025 Jan 9.PMID: 39813819 Free PMC article.
8. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Cavallari LH, Hicks JK, Patel JN, Elchynski AL, Smith DM, Bargal SA, Fleck A, Aquilante CL, Killam SR, Lemke L, Ochi T, Ramsey LB, Haidar CE, Ho T, El Roubay N, Monte AA, Allen JD, Beitelshees AL, Bishop JR, Bousman C, Campbell R, Cicali EJ, Cook KJ, Duong B, Tsermpini EE, Girdwood ST, Gregornik DB, Grimsrud KN, Lamb N, Lee JC, Lopez RO, Mazhindu TA, Morris SA, Nagy M, Nguyen J, Pasternak AL, Petry N, van Schaik RHN, Schultz A, Skaar TC, Al Alishaykh H, Stevenson JM, Stone RM, Tran NK, Tuteja S, Woodahl EL, Yuan LC, Lee CR. *Pharmacogenet Genomics.* 2025 Jan 1;35(1):1-11. doi: 10.1097/FPC.0000000000000547. Epub 2024 Oct 3.PMID: 39485373 Free PMC article.
9. First-trimester maternal tryptophan metabolites, utero-placental (vascular) development and hypertensive disorders of pregnancy: The Rotterdam periconceptional cohort. van Zundert SKM, Broekhuizen M, Mirzaian M, van Rossem L, Danser AHJ, Willemsen SP, Griffioen PH, Koning AHJ, Mulders AGMGJ, van Schaik RHN, Steegers-Theunissen RPM. *Placenta.* 2024 Dec;158:105-112. doi: 10.1016/j.placenta.2024.10.006. Epub 2024 Oct 15.PMID: 39426350 Free article.
10. A vision to the future: value-based laboratory medicine. Plebani M, Cadamuro J, Vermeersch P, Jovičić S,

- Ozben T, Trenti T, McMillan B, Lowe CR, Lennerz J, Macintyre E, Gabelli C, Sandberg S, Padoan A, Wiencek JR, Banfi G, Lubin IM, Orth M, Carobene A, Zima T, Cobbaert CM, van Schaik RHN, Lippi G. *Clin Chem Lab Med*. 2024 Sep 13;62(12):2373-2387. doi: 10.1515/cclm-2024-1022. Print 2024 Nov 26. PMID: 39259894 Free article.
11. Is uracil enough for effective pre-emptive DPD testing? Heersche N, Matic M, Mathijssen RHJ, Coenen MJH, van Schaik RHN. *Clin Chem Lab Med*. 2024 Jul 19;62(12):e255-e256. doi: 10.1515/cclm-2024-0742. Print 2024 Nov 26. PMID: 39022806 Free article. No abstract available. IF 3.8
 12. The impact of maternal vulnerability on stress biomarkers and first-trimester growth: the Rotterdam Periconceptional Cohort (Predict Study). Van Zundert SKM, Van Rossem L, Mirzaian M, Willemsen SP, Voskamp LW, Bastiaansen WAP, Nikpayam D, Griffioen PH, Schilleman WF, Koning AHJ, Van Den Berg SAA, Rousian M, Van Schaik RHN, Steegers-Theunissen RPM. *Hum Reprod*. 2024 Nov 1;39(11):2423-2433. doi: 10.1093/humrep/deae211. PMID: 39298717 Free PMC article.
 13. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants. Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Swen JJ, Touw D, Deneer VHM, van Westrhenen R. *Eur J Hum Genet*. 2024 Nov;32(11):1371-1377. doi: 10.1038/s41431-024-01648-1. Epub 2024 Jul 2. PMID: 38956296
 14. DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogenetics Variation Consortium. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, Turner AJ, van Schaik RHN, Whirl-Carrillo M, Weck KE. *J Mol Diagn*. 2024 Oct;26(10):851-863. doi: 10.1016/j.jmoldx.2024.05.015. Epub 2024 Jul 18. PMID: 39032821 Review.
 15. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. Duarte JD, Thomas CD, Lee CR, Huddart R, Agundez JAG, Baye JF, Gaedigk A, Klein TE, Lanfear DE, Monte AA, Nagy M, Schwab M, Stein CM, Uppugunduri CRS, van Schaik RHN, Donnelly RS, Caudle KE, Luzum JA. *Clin Pharmacol Ther*. 2024 Oct;116(4):939-947. doi: 10.1002/cpt.3351. Epub 2024 Jul 1. PMID: 38951961 Free PMC article.
 16. Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. *Clin Pharmacol Ther*. 2024 Sep;116(3):690-702. doi: 10.1002/cpt.3238. Epub 2024 Mar 18. PMID: 38494911
 17. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD. Knikman JE, Zhai Q, Lunenburg CATC, Henricks LM, Böhringer S, van der Lee M, de Man FM, Offer SM, Shrestha S, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, van Schaik RHN, Gelderblom H, Mathijssen RHJ, Schellens JHM, Cats A, Guchelaar HJ, Swen JJ. *Genome Med*. 2024 Aug 15;16(1):101. doi: 10.1186/s13073-024-01354-z. PMID: 39148102 Free PMC article.
 18. Exploring P-gp as moderator of side effects and effectiveness of risperidone in children and adolescents. Hermans RA, Gangapersad RN, Kloosterboer SM, van Schaik RHN, Hillegers MHJ, Koch BCP, de Winter BCM, Dierckx B. *Eur Neuropsychopharmacol*. 2024 Aug;85:5-7. doi: 10.1016/j.euroneuro.2024.04.002. Epub 2024 Apr 20. PMID: 38643629 No abstract available.
 19. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. Manson LEN, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Swen JJ, Touw DJ, van Westrhenen R, Deneer VHM, Guchelaar HJ. *Eur J Hum Genet*. 2024 Aug;32(8):903-911. doi: 10.1038/s41431-024-01572-4. Epub 2024 Apr 3. PMID: 38570725
 20. Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients. Azzahafi J, van den Broek WWA, Chan Pin Yin DRPP, van der Sange NMR, Sivanesan S, Bofarid S, Peper J, Claassens DMF, Janssen PWA, Harmsze AM, Walhout RJ, Tjon Joe Gin M, Nicastia DM, Langerveld J, Vlachojannis GJ, van Bommel RJ, Appelman Y, van Schaik RHN, Henriques JPS, Kikkert WJ, Ten Berg JM. *JACC Cardiovasc Interv*. 2024 Jul 29;S1936-8798(24)00913-0. doi: 10.1016/j.jcin.2024.06.020. Online ahead of print. PMID: 39217531
 21. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib. Ernst SM, van Marion R, Atmodimedjo PN, de Jonge E, Mathijssen RHJ, Paats MS, de Bruijn P, Koolen SL, van der Thüsen JH, Aerts JGJV, van Schaik RHN, Dubbink HJ, Dingemans AC. *J Thorac Oncol*. 2024 Jul;19(7):995-1006. doi: 10.1016/j.jtho.2024.04.007. Epub 2024 Apr 12. PMID: 38615940 Free article. IF 21.1
 22. Periconceptional Non-medical Maternal Determinants Influence the Tryptophan Metabolism: The Rotterdam Periconceptional Cohort (Predict Study). van Zundert SK, van Rossem L, Mirzaian M, Griffioen PH, Willemsen SP, van Schaik RH, Steegers-Theunissen RP. *Int J Tryptophan Res*. 2024 Jun 12;17:11786469241257816. doi: 10.1177/11786469241257816. eCollection 2024. PMID: 38873365 Free PMC article.
 23. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. de Joode K, Mora AR, van Schaik RHN, Zippelius A, van der Veldt A, Gerard CL, Läubl H, Michielin O, von Moos R, Joergler M, Levesque MP, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex SL, Mathijssen R, Metaxas Y. *J Immunother*. 2024 Jun 1;47(5):190-194. doi: 10.1097/CJI.0000000000000506. Epub 2024 Feb 6. PMID: 38318726
 24. First trimester maternal tryptophan metabolism and embryonic and fetal growth: the Rotterdam Periconceptional Cohort (Predict Study). van Zundert SKM, van Egmond NCM, van Rossem L, Willemsen SP, Griffioen PH, van Schaik RHN, Mirzaian M, Steegers-Theunissen RPM. *Hum Reprod*. 2024 May 2;39(5):912-922. doi: 10.1093/humrep/deae046. PMID: 38498837 Free PMC article.
 25. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium. van der Leest P, Rozendal P, Hinrichs J, van Noesel CJM, Zwaenepoel K, Deiman B, Huijsmans CJJ, van Eijk R, Speel EJM, van Haastert RJ, Ligtenberg MJL, van Schaik RHN, Jansen MPH, Dubbink HJ, de Leng WW, Leers MPG, Tamminga M, van den Broek D, van Kempen LC, Schuuring E. *Clin Chem*. 2024 May 2;70(5):759-767. doi: 10.1093/clinchem/hvae014. PMID: 38484302
 26. Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Karas S, Mathijssen RHJ, van Schaik RHN, Forrest A, Wiltshire T, Bies RR, Innocenti F. *Clin Pharmacol Ther*. 2024 May;115(5):1162-1174. doi: 10.1002/cpt.3190. Epub 2024 Feb 12. PMID: 38344867
 27. TGF- β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma. Crucitta S, Cucchiara F, Marconcini R, Bulleri A, Manacorda S, Capuano A, Cioni D, Nuzzo A, de Jonge E, Mathijssen RHJ, Neri E, van Schaik RHN, Fogli S, Danesi R, Del Re M. *Front Mol Biosci*. 2024 Apr 3;11:1288677. doi: 10.3389/fmols.2024.1288677. eCollection 2024. PMID: 38633217 Free PMC article.

28. The fully automated Sysmex XN-31 hematology analyzer can detect bloodstream form *Trypanosoma brucei*. Khartabil T, van Schaik RH, Haanstra JR, Koelwijn R, Russcher H, van Hellemond JJ. *Diagn Microbiol Infect Dis*. 2024 Apr;108(4):116193. doi: 10.1016/j.diagmicrobio.2024.116193. Epub 2024 Jan 25. PMID: 38295683 Free article.
29. Genetic Polymorphism as a Possible Cause of Severe Postoperative Pain. Govers B, Matic M, van Schaik RHN, Klimek M. *J Clin Pharmacol*. 2024 Mar;64(3):378-381. doi: 10.1002/jcph.2367. Epub 2023 Oct 25. PMID: 37816218 No abstract available.
30. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Swen JJ, Touw D, van Westrhenen R, Deneer VHM, van der Weide J. *Eur J Hum Genet*. 2024 Mar;32(3):278-285. doi: 10.1038/s41431-023-01347-3. Epub 2023 Mar 31. PMID: 37002327 Free PMC article.
31. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate. van der Pol KH, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Risselada A, van Schaik RHN, Swen JJ, Touw D, van der Weide J, van Westrhenen R, Deneer VHM, Houwink EJF, Rongen GA. *Eur J Hum Genet*. 2024 Feb;32(2):155-162. doi: 10.1038/s41431-022-01180-0. Epub 2022 Sep 2. PMID: 36056234 Free PMC article.
32. Determination of cortisone and cortisol in human scalp hair using an improved LC-MS/MS-based method. Mirzaian M, van Zundert SKM, Schilleman WF, Mohseni M, Kuckuck S, van Rossum EFC, van Schaik RHN, van den Berg SAA. *Clin Chem Lab Med*. 2023 Jul 25;62(1):118-127. doi: 10.1515/cclm-2023-0341. Print 2024 Jan 26. PMID: 37485925 Free article.
33. Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk. de Bakker M, Scholte NTB, Oemrawsingh RM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Aksoy I, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Krenning B, de Winter RJ, The SHK, Wardeh AJ, Hermans W, Cramer GE, van Schaik RH, de Rijke YB, Akkerhuis KM, Kardys I, Boersma E; BIOMARCS Investigators †. *J Am Heart Assoc*. 2024 Jan 16;13(2):e031646. doi: 10.1161/JAHA.123.031646. Epub 2024 Jan 12. PMID: 38214281 Free PMC article.
34. Review - The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors. de Joode K, Heersche N, Basak EA, Bins S, van der Veldt AAM, van Schaik RHN, Mathijssen RHJ. *Cancer Treat Rev*. 2024 Jan;122:102662. doi: 10.1016/j.ctrv.2023.102662. Epub 2023 Nov 27. PMID: 38043396 Free article. Review.
35. High-Dose Methylphenidate and Carboxylesterase 1 Genetic Variability in Patients With Attention-Deficit/Hyperactivity Disorder: A Case Series. Westerkamp AC, Pereira RR, Huitema VR, Kouwert EAM, Matic M, van Schaik RHN, Punt N, Schoevers RA, Touw DJ. *J Clin Psychopharmacol*. 2024 Jan-Feb 01;44(1):35-38. doi: 10.1097/JCP.0000000000001772. Epub 2023 Oct 17. PMID: 37851403
36. Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study. Schagen MR, Ulu AN, Francke MI, van de Wetering J, van Buren MC, Schoenmakers S, Matic M, van Schaik RHN, Hesselink DA, de Winter BCM. *Br J Clin Pharmacol*. 2024 Jan;90(1):176-188. doi: 10.1111/bcp.15886. Epub 2023 Sep 4. PMID: 37596793 Free article.
37. A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide. Buck SAJ, Meertens M, van Ooijen FMF, Oomen-de Hoop E, de Jonge E, Coenen MJH, Bergman AM, Koolen SLW, de Wit R, Huitema AD, van Schaik RHN, Mathijssen RHJ. *Biomed Pharmacother*. 2023 Dec 31;169:115890. doi: 10.1016/j.biopha.2023.115890. Epub 2023 Nov 21. PMID: 37988848 Free article.
38. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laïsk T, Figuerêdo J, Muir K, Ito S, Liu X; Biobank Japan Project; Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, McMahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghousaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent ME, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sorensen KD, Borre M, Blot ... See abstract for full author list. *Nat Genet*. 2023 Dec;55(12):2065-2074. doi: 10.1038/s41588-023-01534-4. Epub 2023 Nov 9. PMID: 37945903 Free PMC article.
39. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate. Nijenhuis M, Soree B, Jama WOM, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Rongen GA, van Schaik RHN, Swen JJ, Touw D, van der Weide J, van Westrhenen R, Deneer VHM, Risselada A. *Eur J Hum Genet*. 2023 Dec;31(12):1364-1370. doi: 10.1038/s41431-022-01262-z. Epub 2022 Dec 12. PMID: 36509836 Free PMC article.
40. Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1. de With M, van Doorn L, Kloet E, van Veggel A, Matic M, de Neijis MJ, Oomen-de Hoop E, van Meerten E, van Schaik RHN, Mathijssen RHJ, Bins S. *Clin Pharmacokinet*. 2023 Nov;62(11):1589-1597. doi: 10.1007/s40262-023-01279-7. Epub 2023 Sep 16. PMID: 37715926 Free PMC article.
41. Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness. Hermans RA, Sassen SDT, Kloosterboer SM, Reichart CG, Kouijzer MEJ, de Kroon MMJ, Bastiaansen D, van Altena D, van Schaik RHN, Nasserinejad K, Hillegers MHJ, Koch BCP, Dierckx B, de Winter BCM. *Br J Clin Pharmacol*. 2023 Oct;89(10):3026-3036. doi: 10.1111/bcp.15800. Epub 2023 Jun 13. PMID: 37222228 Free article.
42. Implementation of Pharmacogenetics in First-Line Care: Evaluation of Its Use by General Practitioners. van der Drift D, Simoons M, Koch BCP, Brufau G, Bindels P, Matic M, van Schaik RHN. *Genes (Basel)*. 2023 Sep 22;14(10):1841. doi: 10.3390/genes14101841. PMID: 37895189 Free PMC article.
43. Efficacy and Tolerability of Osimertinib and Sotorasib Combination Treatment for Osimertinib Resistance Caused by KRAS G12C Mutation: A Report of Two Cases. Ernst SM, Uzun S, Paats MS, van Marion R, Atmodimedjo PN, de Jonge E, van Schaik RHN, Aerts JGJV, von der Thüsen JH, Dubbink HJ, Dingemans AC. *JCO Precis Oncol*. 2023 Sep;7:e2300451. doi: 10.1200/PO.23.00451. PMID: 38096473 Free PMC article.
44. CYP3A4 and CYP3A5 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. *J Mol Diagn*. 2023 Sep;25(9):619-629. doi: 10.1016/j.jmoldx.2023.06.008. Epub 2023 Jul 6. PMID: 37419245 Free PMC article. Review. IF 2,6

45. Characterization of Reference Materials for CYP3A4 and CYP3A5: A (GeT-RM) Collaborative Project. Gaedigk A, Boone EC, Turner AJ, van Schaik RHN, Chernova D, Wang WY, Broeckel U, Granfield CA, Hodge JC, Ly RC, Lynnes TC, Mitchell MW, Moyer AM, Oliva J, Kalman LV. *J Mol Diagn.* 2023 Sep;25(9):655-664. doi: 10.1016/j.jmoldx.2023.06.005. Epub 2023 Jun 23. PMID: 37354993 Free PMC article. IF 2,6
46. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Touw DJ, van der Weide J, van Westrhenen R, Deneer VHM, Guchelaar HJ, Swen JJ. *Eur J Hum Genet.* 2023 Sep;31(9):1088-1089. doi: 10.1038/s41431-023-01315-x. PMID: 36797469 Free PMC article. No abstract available.
47. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Touw DJ, van der Weide J, van Westrhenen R, Deneer VHM, Guchelaar HJ, Swen JJ. *Eur J Hum Genet.* 2023 Sep;31(9):982-987. doi: 10.1038/s41431-022-01243-2. Epub 2022 Nov 28. PMID: 36443464 Free PMC article. Review.
48. CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients. van Eerden RAG, IJzerman NS, van Meekeren M, Oomen-de Hoop E, Guchelaar NAD, Visser AMW, Matic M, van Schaik RHN, de Bruijn P, Moes DAR, Jobse PA, Gelderblom H, Huitema ADR, Steeghs N, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. *Clin Pharmacokinet.* 2023 Aug;62(8):1129-1139. doi: 10.1007/s40262-023-01260-4. Epub 2023 Jun 13. PMID: 37310647 Free PMC article.
49. Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMARCS cohort. Gürgöze MT, Akkerhuis KM, Oemrawsingh RM, Umans VAWM, Kietselaer B, Schotborgh CE, Ronner E, Lenderink T, Aksoy I, van der Harst P, Asselbergh FW, Maas AC, Oude Ophuis AJ, Krenning B, de Winter RJ, The SHK, Wardeh AJ, Hermans WRM, Cramer GE, van Gorp I, de Rijke YB, van Schaik RHN, Boersma E. *Eur Heart J Acute Cardiovasc Care.* 2023 Jul 7;12(7):451-461. doi: 10.1093/ehjacc/zuad042. PMID: 37096818 Free PMC article.
50. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. Veerman GDM, Boosman RJ, Jebbink M, Oomen-de Hoop E, van der Wekken AJ, Bahce I, Hendriks LEL, Croes S, Steendam CMJ, de Jonge E, Koolen SLW, Steeghs N, van Schaik RHN, Smit EF, Dingemans AC, Huitema ADR, Mathijssen RHJ. *EClinicalMedicine.* 2023 Apr 13;59:101955. doi: 10.1016/j.eclinm.2023.101955. eCollection 2023 May. PMID: 37125403 Free PMC article.
51. The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress. van Schaik RH, Manolopoulos VG, Daly AK, Niemi M, Zukic B, Patrinos GP, Primorac D, Swen JJ, Ingelman-Sundberg M, Morris T, Molden E, Müller D, Pavlovic S, Russmann S, Ansari M, Henricks LM, den Broek WV, Florindi F, Bozina N, Akin D, Christrup L, Llerena A, Sipeky C, Stankovic S. *Pharmacogenomics.* 2023 Apr;24(5):243-246. doi: 10.2217/pgs-2023-0013. Epub 2023 Apr 4. PMID: 37014361
52. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, van Schaik RHN, Mathijssen RHJ, Largiadèr CR; The Working Group on the Implementation of DPD-deficiency Testing in Europe. *ESMO Open.* 2023 Apr;8(2):101197. doi: 10.1016/j.esmoop.2023.101197. Epub 2023 Mar 28. PMID: 36989883 Free PMC article. IF 8,7
53. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale. Agema BC, Buijs SM, Sassen SDT, Mürdter TE, Schwab M, Koch BCP, Jager A, van Schaik RHN, Mathijssen RHJ, Koolen SLW. *Biomed Pharmacother.* 2023 Apr;160:114369. doi: 10.1016/j.biopha.2023.114369. Epub 2023 Feb 6. PMID: 36753957 Free article.
54. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD. de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN, Bins S. *Biomed Pharmacother.* 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9. PMID: 36630849 Free article.
55. Simultaneous quantification of tryptophan metabolites by liquid chromatography tandem mass spectrometry during early human pregnancy. van Zundert SKM, Griffioen PH, van Rossem L, Willemsen SP, de Rijke YB, van Schaik RHN, Steegers-Theunissen RPM, Mirzaian M. *Clin Chem Lab Med.* 2022 Dec 5;61(3):442-451. doi: 10.1515/cclm-2022-0790. Print 2023 Feb 23. PMID: 36458576 Free article.
56. Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up. Pruis MA, Veerman GDM, Hassing HC, Lanser DAC, Paats MS, van Schaik RHN, Mathijssen RHJ, Manintveld O, Dingemans AC. *JACC CardioOncol.* 2023 Jan 17;5(1):102-113. doi: 10.1016/j.jaccao.2022.09.006. eCollection 2023 Feb. PMID: 36875894 Free PMC article. IF 13,6
57. The Clinical Implementation of CYP2C19 Genotyping in Patients with an Acute Coronary Syndrome: Insights From the FORCE-ACS Registry. Azzahafi J, Broek WWAVD, Chan Pin Yin DRPP, Harmsze AM, van Schaik RHN, Ten Berg JM. *J Cardiovasc Pharmacol Ther.* 2023 Jan-Dec;28:10742484231210704. doi: 10.1177/10742484231210704. PMID: 37899583 Free article.
58. Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study. Azzahafi J, Bergmeijer TO, van den Broek WWA, Chan Pin Yin DRPP, Rayhi S, Peper J, Bor WL, Claassens DMF, van Schaik RHN, Ten Berg JM. *Front Pharmacol.* 2022 Dec 5;13:1032995. doi: 10.3389/fphar.2022.1032995. eCollection 2022. PMID: 36545312 Free PMC article.
59. The Predictive Power of the 14-51 Ng/L High Sensitive Troponin T (hsTnT) Values for Predicting Cardiac Revascularization in a Clinical Setting. De Jongh FW, Pouwels S, De Jongh MC, Dubois EA, van Schaik RHN. *J Clin Med.* 2022 Dec 1;11(23):7147. doi: 10.3390/jcm11237147. PMID: 36498720 Free PMC article.
60. PharmVar GeneFocus: CYP3A5. Rodriguez-Antona C, Savieo JL, Lauschke VM, Sangkuhl K, Drögemöller BI, Wang D, van Schaik RHN, Gilep AA, Peter AP, Boone EC, Ramey BE, Klein TE, Whirl-Carrillo M, Pratt VM, Gaedigk A. *Clin Pharmacol Ther.* 2022 Dec;112(6):1159-1171. doi: 10.1002/cpt.2563. Epub 2022 Mar 29. PMID: 35202484 Free PMC article. Review.
61. TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. *J Mol Diagn.* 2022 Oct;24(10):1051-1063. doi: 10.1016/j.jmoldx.2022.06.007. Epub 2022 Aug 2. PMID: 35931343 Free PMC article. Review.
62. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. Brouwer JM, Nijenhuis M, Soree B, Guchelaar HJ, Swen JJ, van Schaik RHN, Weide JV, Rongen GAPJM, Buunk AM, de Boer-Veger NJ, Houwink EJF, van Westrhenen R, Wilffert B, Deneer VHM, Mulder H. *Eur J Hum Genet.* 2022 Oct;30(10):1114-1120. doi: 10.1038/s41431-021-01004-7. Epub 2021 Nov 16. PMID: 34782755 Free PMC article.

63. Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJJ, Mulder H, Rongen GAPJM, Weide JV, Wilffert B, Swen JJ, Guchelaar HJ, Deneer VHM, van Schaik RHN. *Eur J Hum Genet.* 2022 Oct;30(10):1196. doi: 10.1038/s41431-021-00969-9. PMID: 34565798 Free PMC article. No abstract available.
64. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Matic M, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJJ, Mulder H, Rongen GAPJM, Weide JV, Wilffert B, Swen JJ, Guchelaar HJ, Deneer VHM, van Schaik RHN. *Eur J Hum Genet.* 2022 Oct;30(10):1105-1113. doi: 10.1038/s41431-021-00920-y. Epub 2021 Jul 15. PMID: 34267337 Free PMC article.
65. Call for Manuscript Submissions for a Thematic eJIFCC Issue on "Pharmacogenetics and Personalized Therapy". van Schaik RHN, Stankovic S. *EJIFCC.* 2022 Aug 8;33(2):79. eCollection 2022 Aug. PMID: 36313913 Free PMC article. No abstract available.
66. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial. Braal CL, Westenberg JD, Buijs SM, Abrams S, Mulder TAM, van Schaik RHN, Koolen SLW, Jager A, Mathijssen RHJ. *Breast Cancer Res Treat.* 2022 Aug;195(1):65-74. doi: 10.1007/s10549-022-06643-y. Epub 2022 Jul 16. PMID: 35842520 Free PMC article. Clinical Trial.
67. Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors. Karas S, Mathijssen RHJ, van Schaik RHN, Forrest A, Wiltshire T, Innocenti F, Bies RR. *Clin Pharmacol Ther.* 2022 Aug;112(2):316-326. doi: 10.1002/cpt.2621. Epub 2022 May 18. PMID: 35467016 Free PMC article.
68. Dutch National Round Robin Trial on Plasma-Derived Circulating Cell-Free DNA Extraction Methods Routinely Used in Clinical Pathology for Molecular Tumor Profiling. van der Leest P, Ketelaar EM, van Noesel CJM, van den Broek D, van Boerdonk RAA, Deiman B, Rifaela N, van der Geize R, Huijsmans CJJ, Speel EJM, Geerlings MJ, van Schaik RHN, Jansen MPH, Dane-Vogelaar R, Driehuis E, Leers MPG, Sidorenkov G, Tamminga M, van Kempen LC, Schuurin E. *Clin Chem.* 2022 Jul 3;68(7):963-972. doi: 10.1093/clinchem/hvac069. PMID: 35616097 Clinical Trial. IF 9,3
69. DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events. de With M, Brufau G, van den Berg LA, de Man FM, Trajkovic M, Thijs MF, Castel R, Vermeer HJ, El Bouazzaoui S, van Hemel A, Matic M, Mathijssen RHJ, Bins S, van Schaik RHN. *JCO Precis Oncol.* 2022 Jul;6:e2200180. doi: 10.1200/PO.22.00180. PMID: 35862869 IF 7,9
70. A Population Pharmacokinetic Model of Whole-Blood and Intracellular Tacrolimus in Kidney Transplant Recipients. Franken LG, Francke MI, Andrews LM, van Schaik RHN, Li Y, de Wit LEA, Baan CC, Hesselink DA, de Winter BCM. *Eur J Drug Metab Pharmacokinet.* 2022 Jul;47(4):523-535. doi: 10.1007/s13318-022-00767-8. Epub 2022 Apr 20. PMID: 35442010 Free PMC article.
71. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. de With M, Knikman J, de Man FM, Lunenburg CATC, Henricks LM, van Kuilenburg ABP, Maring JG, van Staveren MC, de Vries N, Rosing H, Beijnen JH, Pluim D, Modak A, Imholz ALT, van Schaik RHN, Schellens JHM, Gelderblom H, Cats A, Guchelaar HJ, Mathijssen RHJ, Swen JJ, Meulendijks D. *Clin Pharmacol Ther.* 2022 Jul;112(1):62-68. doi: 10.1002/cpt.2608. Epub 2022 May 4. PMID: 35397172 Free PMC article.
72. The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review. Yalgin N, Flint RB, van Schaik RHN, Simons SHP, Allegaert K. *Pharmacogenomics Pers Med.* 2022 Jun 30;15:675-696. doi: 10.2147/PGPM.S350205. eCollection 2022. PMID: 35795337 Free PMC article. Review.
73. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer. Heersche N, Veerman GDM, de With M, Bins S, Assaraf YG, Dingemans AC, van Schaik RHN, Mathijssen RHJ, Jansman FGA. *Drug Resist Updat.* 2022 May;62:100832. doi: 10.1016/j.drup.2022.100832. Epub 2022 Apr 5. PMID: 35427871 Free article. Review. IF 24,3
74. Influence of Receptor Polymorphisms on the Response to α -Adrenergic Receptor Blockers in Pheochromocytoma Patients. Berends AMA, Bolhuis MS, Nolte IM, Buitenwerf E, Links TP, Timmers HJLM, Feelders RA, Eekhoff EMW, Corssmit EPM, Bisschop PH, Haak HR, van Schaik RHN, El Bouazzaoui S, Wilffert B, Kerstens MN. *Biomedicines.* 2022 Apr 13;10(4):896. doi: 10.3390/biomedicines10040896. PMID: 35453646 Free PMC article.
75. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles GDM, de With M, Bins S, Assaraf YG, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Menegaux F, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Lu YJ, Watya S, Vega A, Kogevinas M, Wiklund F, Penney KL, Huff CD, Teixeira MR, Multigner L, Leach RJ, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, De Ruyck K, Ost P, Razack A, Newcomb LF, Fowke JH, Gamulin M, Abraham A, Claessens F, Castelao JE, Townsend PA, Crawford DC, Petrovics G, van Schaik RHN, Parent MÉ, Hu JJ, Zheng W; UKGPCS collaborators; APCB (Australian Prostate Cancer BioResource); NC-LA PCaP Investigators; IMPACT Study Steering Committee and Collaborators; Canary PASS Investigators; Profile Study Steering Committee; PRACTICAL Consortium; Mills IG, Andriassen OA, Dale AM, Seibert TM. *Prostate Cancer Prostatic Dis.* 2022 Apr;25(4):755-761. doi: 10.1038/s41391-022-00497-7. Epub 2022 Feb 12. PMID: 35152271 Free PMC article.
76. A randomized crossover study comparing different tacrolimus formulations to reduce inpatient variability in tacrolimus exposure in kidney transplant recipients. Bunthof KWL, Al-Hassany L, Nakshbandi G, Hesselink DA, van Schaik RHN, Ten Dam MAGJ, Baas MC, Hilbrands LB, van Gelder T. *Clin Transl Sci.* 2022 Apr;15(4):930-941. doi: 10.1111/cts.13206. Epub 2021 Dec 15. PMID: 34905302 Free PMC article. Clinical Trial.
77. Donor-Derived Cell-Free DNA for the Detection of Heart Allograft Injury: The Impact of the Timing of the Liquid Biopsy. Verhoeven JGHP, Hesselink DA, Peeters AMA, de Jonge E, von der Thüsen JH, van Schaik RHN, Matic M, Baan CC, Manintveld OC, Boer K. *Transpl Int.* 2022 Mar 21;35:10122. doi: 10.3389/ft.2022.10122. eCollection 2022. PMID: 35387397 Free PMC article.
78. Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment. Buck SAJ, Braal CL, Hofman MM, Oomen-de Hoop E, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, Hussaarts KGAM, Vastbinder MB, van Rossum-Schornagel QC, van Schaik RHN, Jager A, Koolen SLW, Mathijssen RHJ. *Ther Adv Med Oncol.* 2022 Mar 17;14:17588359221081075. doi: 10.1177/17588359221081075. eCollection 2022. PMID: 35321309 Free PMC article.
79. A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity. Akin S, Schriek P, van Nieuwkoop C, Neuman RI, Meynaar I, van Helden EJ, Bouazzaoui HE, Baak R, Veuger M, Mairuhu RATA, van den Berg L, van Driel V, Visser LE, de Jonge E, Garrelds IM, Duynstee JFAB, van Rooden JK, Ludikhuis J, Verdonk K, Caliskan K, Jansen T, van Schaik RHN, Danser AHJ. *J Hypertens.* 2022 Mar 1;40(3):606-614. doi: 10.1097/HJH.0000000000003054. PMID: 34862332 Free PMC article.
80. UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. Hulshof EC, de With M, de Man FM, Creemers GJ, Deiman BALM, Swen JJ, Houterman S, Koolen SLW, Bins

- S, Thijs AMJ, Laven MMJ, Hövels AM, Luelmo SAC, Houtsma D, Shulman K, McLeod HL, van Schaik RHN, Guchelaar HJ, Mathijssen RHJ, Gelderblom H, Deenen MJ. *Eur J Cancer*. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. PMID: 34998046 Free article. IF 7,6
81. [Genotype-guided antithrombotic therapy]. van den Broek WWA, Azzahafi J, van Schaik RHN, Ten Berg JM. *Ned Tijdschr Geneesk*. 2022 Jan 24;166:D6172. PMID: 35138719 Dutch.
82. Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. van der Perk MEM, Broer L, Yasui Y, Robison LL, Hudson MM, Laven JSE, van der Pal HJ, Tissing WJE, Versluys B, Bresters D, Kaspers GJL, de Vries ACH, Lambalk CB, Overbeek A, Loonen JJ, Beerendonk CCM, Byrne J, Berger C, Clemens E, Dirksen U, Winther JF, Fosså SD, Grabow D, Muraca M, Kaiser M, Kepák T, Kruseova J, Modan-Moses D, Spix C, Zolk O, Kaatsch P, Krijthe JH, Kremer LCM, Brooke RJ, Baedke JL, van Schaik RHN, van den Anker JN, Uitterlinden AG, Bos AME, van Leeuwen FE, van Dulmen-den Broeder E, van der Kooi ALF, van den Heuvel-Eibrink MM, On Behalf Of The PanCareLIFE Consortium. *Cancers (Basel)*. 2021 Sep 13;13(18):4598. doi: 10.3390/cancers13184598. PMID: 34572825 Free PMC article. IF5,2
83. Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy. Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. *J Mol Diagn*. 2021 Sep;23(9):1047-1064. doi: 10.1016/j.jmoldx.2021.05.013. Epub 2021 Jun 10. PMID: 34118403 Free PMC article. Review.
84. What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Considerations on pre-analytical aspects by the IFCC workgroup cDNA. Danesi R, Lo YMD, Oellerich M, Beck J, Galbiati S, Re MD, Lianidou E, Neumaier M, van Schaik RHN. *Clin Chim Acta*. 2021 Sep;520:168-171. doi: 10.1016/j.cca.2021.05.033. Epub 2021 Jun 1. PMID: 34081934 Free article. IF 5,0
85. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. van der Sijde F, Azmani Z, Besselink MG, Bonsing BA, de Groot JWB, Groot Koerkamp B, Haberkorn BCM, Homs MYV, van IJcken WFJ, Janssen QP, Lolkema MP, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, van Schaik RHN, Wilmink JW, Vietsch EE, van Eijck CHJ. *Ther Adv Med Oncol*. 2021 Aug 18;13:17588359211033704. doi: 10.1177/17588359211033704. eCollection 2021. PMID: 34422118 Free PMC article.
86. Is monitoring of antiplatelet therapy by light transmission aggregometry dependent on instrument and reagent used? Monteyne T, Heireman L, Hemelsoet D, van Schaik RHN, Devreese KMJ. *Int J Lab Hematol*. 2021 Aug;43(4):786-794. doi: 10.1111/ijlh.13579. Epub 2021 Jun 15. PMID: 34129280
87. CYP3A4 \square 22 Genotyping in Clinical Practice: Ready for Implementation? Mulder TAM, van Eerden RAG, de With M, Elens L, Hesselink DA, Matic M, Bins S, Mathijssen RHJ, van Schaik RHN. *Front Genet*. 2021 Jul 8;12:711943. doi: 10.3389/fgene.2021.711943. eCollection 2021. PMID: 34306041 Free PMC article. Review.
88. Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial. Francke MI, Andrews LM, Le HL, van de Wetering J, Claessen-van Groningen MC, van Gelder T, van Schaik RHN, van der Holt B, de Winter BCM, Hesselink DA. *Clin Pharmacol Ther*. 2021 Jul;110(1):169-178. doi: 10.1002/cpt.2163. Epub 2021 Feb 23. PMID: 33452682 Free PMC article.
89. Corrigendum to Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium journal of critical care 57 (2020) 203-207. Zoran Trogrlić, van der Jagt M, Osse RJ, Devlin JW, Nieboer D, Koch BCP, van Schaik RHN, Hunfeld NGM. *J Crit Care*. 2021 Jun;63:282. doi: 10.1016/j.jccr.2020.10.004. Epub 2020 Nov 4. PMID: 33158611 No abstract available.
90. Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice. van Westrhenen R, van Schaik RHN, van Gelder T, Birkenhager TK, Bakker PR, Houwink EJJ, Bet PM, Hoogendijk WJG, van Weelden-Hulshof MJM. *Front Pharmacol*. 2021 Apr 12;12:640032. doi: 10.3389/fphar.2021.640032. eCollection 2021. PMID: 33995044 Free PMC article. Review.
91. Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, Marquet P, Molinaro M, Noceti O, Pattanaik S, Pawinski T, Seger C, Shipkova M, Swen JJ, van Gelder T, Venkataramanan R, Wieland E, Woillard JB, Zwart TC, Barten MJ, Budde K, Dieterlen MT, Elens L, Haufroid V, Masuda S, Millan O, Mizuno T, Moes DJAR, Oellerich M, Picard N, Salzmann L, Tönshoff B, van Schaik RHN, Vethe NT, Vinks AA, Wallemacq P, Åsberg A, Langman LJ. *Ther Drug Monit*. 2021 Apr 1;43(2):150-200. doi: 10.1097/FTD.0000000000000871. PMID: 33711005 Review.
92. Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients. Francke MI, Hesselink DA, Li Y, Koch BCP, de Wit LEA, van Schaik RHN, Yang L, Baan CC, van Gelder T, de Winter BCM. *Br J Clin Pharmacol*. 2021 Apr;87(4):1918-1929. doi: 10.1111/bcp.14585. Epub 2020 Nov 24. PMID: 33025649 Free PMC article.
93. Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. de With M, Hurkmans DP, Oomen-de Hoop E, Lalouti A, Bins S, El Bouazzaoui S, van Brakel M, Debets R, Aerts JGJV, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM. *Cancers (Basel)*. 2021 Mar 18;13(6):1370. doi: 10.3390/cancers13061370. PMID: 33803602 Free PMC article.
94. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokołorczyk D, Lubiński J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghousaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, M... See abstract for full author list \square *Nat Genet*. 2021 Mar;53(3):413. doi: 10.1038/s41588-021-00786-2. PMID: 33473200 No abstract available.
95. Predicting Unacceptable Pain in Cardiac Surgery Patients Receiving Morphine Maintenance and Rescue Doses: A Model-Based Pharmacokinetic-Pharmacodynamic Analysis. Gouloze SC, Krekels EH, Saleh MA, Ahlers SJ, Väitalo PA, van Dongen EP, van Schaik RH, Hankemeier T, Tibboel D, Knibbe CAJ. *Anesth Analg*. 2021 Mar 1;132(3):726-734. doi: 10.1213/ANE.0000000000005228. PMID: 33122543
96. Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Kloosterboer SM, de Winter BCM, Reichart CG, Kouijzer MEJ, de Kroon MMJ, van Daalen E, Ester WA, Rieken R, Dieleman GC, van Altena D, Bartelds B, van Schaik RHN, Nasserinejad K,

- Hillegers MHJ, van Gelder T, Dierckx B, Koch BCP. *Br J Clin Pharmacol*. 2021 Mar;87(3):1069-1081. doi: 10.1111/bcp.14465. Epub 2020 Jul 26. PMID: 32643213 Free PMC article.
97. Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy. Mulder TAM, de With M, Del Re M, Danesi R, Mathijssen RHJ, van Schaik RHN. *Cancers (Basel)*. 2021 Feb 12;13(4):771. doi: 10.3390/cancers13040771. PMID: 33673305 Free PMC article. Review. IF 5,2
98. Temporal Evolution of Serum Concentrations of High-Sensitivity Cardiac Troponin During 1 Year After Acute Coronary Syndrome Admission. van den Berg VJ, Oemrawsingh RM, Umans VAWM, Kardys I, Asselbergs FW, van der Harst P, Hoefler IE, Kietselaer B, Lenderink T, Oude Ophuis AJ, van Schaik RH, de Winter RJ, Akkerhuis KM, Boersma E; BIOMARCS investigators *. *J Am Heart Assoc*. 2021 Jan 5;10(1):e017393. doi: 10.1161/JAHA.120.017393. Epub 2020 Dec 16. PMID: 33325242 Free PMC article.
99. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubiński J, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder MA, Iversen P, Batra J, Chambers S, Moya L, Horvath L, Clements JA, Tilley W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordström T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein SJ, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM Jr, Hamilton RJ, Fleshner NE, Finelli A, Parent ME, Stanford JL, Ostrander EA, Geybels MS, Koutros S, Freeman LEB, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, M... See abstract for full author list. *Nat Genet*. 2021 Jan;53(1):65-75. doi: 10.1038/s41588-020-00748-0. Epub 2021 Jan 4. PMID: 33398198 Free PMC article.
100. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors. Del Re M, van Schaik RHN, Fogli S, Mathijssen RHJ, Cucchiara F, Capuano A, Scavone C, Jenster GW, Danesi R. *Biochim Biophys Acta Rev Cancer*. 2021 Jan;1875(1):188463. doi: 10.1016/j.bbcan.2020.188463. Epub 2020 Nov 1. PMID: 33137405 Review.
101. Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. Bos MK, Nasserinejad K, Jansen MPH, Angus L, Atmodimedjo PN, de Jonge E, Dinjens WNM, van Schaik RHN, Del Re M, Dubbink HJ, Sleijfer S, Martens JWM. *Mol Oncol*. 2021 Jan;15(1):57-66. doi: 10.1002/1878-0261.12827. Epub 2020 Oct 31. PMID: 33070443 Free PMC article.
102. Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMARCS study. van den Berg VJ, Umans VAWM, Brankovic M, Oemrawsingh RM, Asselbergs FW, van der Harst P, Hoefler IE, Kietselaer B, Crijns HJGM, Lenderink T, Oude Ophuis AJ, van Schaik RH, Kardys I, Boersma E, Akkerhuis KM; BIOMARCS investigators. *Clin Chem Lab Med*. 2020 Nov 26;58(12):2099-2106. doi: 10.1515/cclm-2019-1320. PMID: 32383686 Free article.
103. The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients. Taron M, Llerena A, Manolopoulos VG, Rodriguez-Antona C, Stankovic S, van Schaik RHN. *Drug Metab Pers Ther*. 2020 Nov 13;35(4). doi: 10.1515/dmpt-2020-0172. PMID: 34704693 No abstract available. IF 1,0
104. Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. Steendam CMJ, Veerman GDM, Pruis MA, Atmodimedjo P, Paats MS, van der Leest C, von der Thüsen JH, Yick DCY, Oomen-de Hoop E, Koolen SLW, Dinjens WNM, van Schaik RHN, Mathijssen RHJ, Aerts JGJV, Dubbink HJ, Dingemans AC. *Cancers (Basel)*. 2020 Oct 29;12(11):3179. doi: 10.3390/cancers12113179. PMID: 33138052 Free PMC article.
105. Editorial: Liquid Biopsy as a Tool for Precision Oncology: New Challenges to Assess Clinical Response. Ravegnini G, Del Re M, Grolla AA, van Schaik RHN, Angelini S. *Front Pharmacol*. 2020 Oct 7;11:598261. doi: 10.3389/fphar.2020.598261. eCollection 2020. PMID: 33117183 Free PMC article. No abstract available.
106. Pharmacogenetics in Psychiatry: An Update on Clinical Usability. van Schaik RHN, Müller DJ, Serretti A, Ingelman-Sundberg M. *Front Pharmacol*. 2020 Sep 11;11:575540. doi: 10.3389/fphar.2020.575540. eCollection 2020. PMID: 33041820 Free PMC article. Review. IF 4,4
107. Search for a practical approach for detection of clopidogrel resistance: Comparison of light transmission aggregometry and INNOVANCE® PFA P2Y cartridge and correlation with CYP2C19 variants. Heireman L, Monteyne T, Hemelsoet D, van Schaik RHN, Devreese KMJ. *Int J Lab Hematol*. 2020 Aug;42(4):e189-e191. doi: 10.1111/ijlh.13240. Epub 2020 May 19. PMID: 32427413 No abstract available.
108. [Pharmacogenetics in daily practice]. van Gelder T, van Schaik RHN. *Ned Tijdschr Geneesk*. 2020 Jun 4;164:D4191. PMID: 32608920 Dutch.
109. Pharmacogenomic response of low dose haloperidol in critically ill adults with delirium. Trogrić Z, van der Jagt M, Osse RJ, Devlin JW, Nieboer D, Koch BCP, van Schaik RHN, Hunfeld NGM. *J Crit Care*. 2020 Jun;57:203-207. doi: 10.1016/j.jccr.2020.03.001. Epub 2020 Mar 4. PMID: 32208328
110. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. Hurkmans DP, Basak EA, Schepers N, Oomen-De Hoop E, Van der Leest CH, El Bouazzaoui S, Bins S, Koolen SLW, Sleijfer S, Van der Veldt AAM, Debets R, Van Schaik RHN, Aerts JGJV, Mathijssen RHJ. *J Immunother Cancer*. 2020 May;8(1):e000586. doi: 10.1136/jitc-2020-000586. PMID: 32461348 Free PMC article.
111. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Swen JJ, Guchelaar HJ. *Eur J Hum Genet*. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19. PMID: 31745289 Free PMC article.
112. Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Agema BC, Koolen SLW, With M, Doorn NV, Heersche N, Hoop EO, Visser S, Aerts JGJV, Bins S, Schaik RHN, Mathijssen RHJ. *Genes (Basel)*. 2020 Mar 27;11(4):358. doi: 10.3390/genes11040358. PMID: 32230800 Free PMC article.
113. Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. Karas S, Etheridge AS, Tsakalozou E, Ramirez J, Cecchin E, van Schaik RHN, Toffoli G, Ratain MJ, Mathijssen RHJ, Forrest A, Bies RR, Innocenti F. *AAPS J*. 2020 Mar 17;22(3):59. doi: 10.1208/s12248-020-0429-4. PMID: 32185579
114. The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Belderbos BPS, de With M, Singh RK, Agema BC, El Bouazzaoui S, Oomen-de Hoop E, de Wit R, van Schaik RHN, Mathijssen RHJ, Bins S. *Cancer Chemother Pharmacol*. 2020 Mar;85(3):547-553. doi: 10.1007/s00280-019-04011-0. Epub 2020 Jan 1. PMID: 31893292 Clinical Trial.
115. OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery. Matic M, de Hoogd S, de Wildt SN, Tibboel D, Knibbe CA, van Schaik RH. *Pharmacogenomics*. 2020

116. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder. Simoons M, Mulder H, Appeldoorn JTY, Risselada AJ, Schene AH, van Schaik RHN, van Roon EN, Ruhé EG. *Psychiatr Genet.* 2020 Feb;30(1):19-29. doi: 10.1097/YPG.0000000000000244.PMID: 31634334
117. Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity. van den Broek D, Hiltermann TJN, Biesma B, Dinjens WNM, 't Hart NA, Hinrichs JWJ, Leers MPG, Monkhorst K, van Oosterhout M, Scharnhorst V, Schuurung E, Speel EM, van den Heuvel MM, van Schaik RHN, van der Thüsen J, Willems SM, de Visser L, Ligtenberg MJL. *Front Oncol.* 2020 Jan 22;9:1521. doi: 10.3389/fonc.2019.01521. eCollection 2019.PMID: 32039011 Free PMC article. Review.
118. Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. Chenoweth MJ, Giacomini KM, Pirmohamed M, Hill SL, van Schaik RHN, Schwab M, Shuldiner AR, Relling MV, Tyndale RF. *Clin Pharmacol Ther.* 2020 Jan;107(1):57-61. doi: 10.1002/cpt.1664. Epub 2019 Nov 6.PMID: 31696505 Free PMC article. No abstract available.
119. Serum magnesium, hepatocyte nuclear factor 1 β genotype and post-transplant diabetes mellitus: a prospective study. van der Burgh AC, Moes A, Kieboom BCT, van Gelder T, Zietse R, van Schaik RHN, Hesselink DA, Hoorn EJ. *Nephrol Dial Transplant.* 2020 Jan 1;35(1):176-183. doi: 10.1093/ndt/gfz145.PMID: 31361318 Clinical Trial.
120. Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results. Steendam CMJ, Atmodimedjo P, de Jonge E, Paats MS, van der Leest C, Oomen-de Hoop E, Jansen MPH, Del Re M, van der Thüsen JH, Dinjens WNM, van Schaik RHN, Aerts JGJV, Dubbink HJ; Erasmus MC Cancer Institute. *JCO Precis Oncol.* 2019 Dec;3:1-9. doi: 10.1200/PO.18.00401.PMID: 35100738
121. Circulating tumor DNA and the future of EGFR-mutant lung cancer treatment. Del Re M, Addeo A, Passaro A, Petrini I, van Schaik RH, Danesi R. *Pharmacogenomics.* 2019 Dec;20(18):1255-1257. doi: 10.2217/pgs-2019-0150.PMID: 31829835 No abstract available.
122. Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma. Goey AK, With M, Agema BC, Hoop EO, Singh RK, van der Veldt AA, Mathijssen RH, van Schaik RH, Bins S. *Pharmacogenomics.* 2019 Dec;20(18):1283-1290. doi: 10.2217/pgs-2019-0101.PMID: 31829834
123. Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [*Cancer Treatm. Rev.* 74 (2019) 21-28]. Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. *Cancer Treat Rev.* 2019 Dec;81:101913. doi: 10.1016/j.ctrv.2019.101913. Epub 2019 Nov 6.PMID: 31706687 Free article. No abstract available.
124. Circulating biomarkers of response to immunotherapy in cancer treatment. Del Re M, Gianfilippo G, Crucitta S, Addeo A, van Schaik RH, Danesi R. *Pharmacogenomics.* 2019 Dec;20(18):1247-1249. doi: 10.2217/pgs-2019-0117. Epub 2019 Nov 6.PMID: 31691637 No abstract available.
125. Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial). van der Schans J, Hak E, Postma M, Breuning L, Brouwers JRB, Ditters K, Jansen PAF, Kok RM, Maring JG, van Marum R, Mulder H, Nanninga J, Oude Voshaar RC, Risselada AJ, Vleugel L, Stek M, van Schaik RHN, Berm EJJ, Wilffert B. *J Clin Psychopharmacol.* 2019 Nov/Dec;39(6):583-590. doi: 10.1097/JCP.0000000000001129.PMID: 31688392 Clinical Trial.
126. 4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation. Sipeky C, Llerena A, Manolopoulos VG, Pearson S, Mlakar V, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, Ansari M, Drago F, van Schaik RH. *Pharmacogenomics.* 2019 Oct;20(15):1063-1069. doi: 10.2217/pgs-2019-0095.PMID: 31588876
127. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose. Berger FA, Mulder MB, Ten Bosch-Dijksman W, van Schaik RHN, Coenen S, de Winter BCM. *Br J Clin Pharmacol.* 2019 Aug;85(8):1852-1854. doi: 10.1111/bcp.13958. Epub 2019 Jun 12.PMID: 31190414 Free PMC article.
128. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. Hurkmans DP, Verhoeven JGHP, de Leur K, Boer K, Joosse A, Baan CC, van der Thüsen JH, van Schaik RHN, Mathijssen RHJ, van der Veldt AAM, Hesselink DA. *J Immunother Cancer.* 2019 Jul 12;7(1):182. doi: 10.1186/s40425-019-0653-6.PMID: 31300068 Free PMC article.
129. Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. Karas Kuželički N, Prodan Žitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, Simmaco M, Ansari M, Pazzagli M, Di Resta C, Brandslund I, Schwab M, Vermeersch P, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Stingl JC, van Schaik RH, Manolopoulos VG, Marc J; Pharmacogenomics Education Working Group (PGxEWG); European Society of Pharmacogenomics and Personalized Therapy (ESPT). *Pharmacogenomics.* 2019 Jun;20(9):643-657. doi: 10.2217/pgs-2019-0009.PMID: 31250730 Free article.
130. 4th ESPT summer school: precision medicine and personalised health. Mlakar V, Marc J, Manolopoulos VG, Cascorbi I, Stanković S, Llerena A, Simmaco M, Visvikis-Siest S, Amstutz U, Sipeky C, Meyer UA, Meier-Abt P, van Schaik RH, Ansari M. *Pharmacogenomics.* 2019 May;20(7):471-474. doi: 10.2217/pgs-2019-0008.PMID: 31124416
131. Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW. *Clin Pharmacokinet.* 2019 May;58(5):651-658. doi: 10.1007/s40262-018-0719-5.PMID: 30367352 Free PMC article. Clinical Trial.
132. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. Hussaarts KGAM, Hurkmans DP, Oomen-de Hoop E, van Harten LJ, Berghuis S, van Alphen RJ, Spierings LEA, van Rossum-Schornagel QC, Vastbinder MB, van Schaik RHN, van Gelder T, Jager A, van Leeuwen RWF, Mathijssen RHJ. *Cancers (Basel).* 2019 Mar 22;11(3):403. doi: 10.3390/cancers11030403.PMID: 30909366 Free PMC article.
133. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R. *Cancer Treat Rev.* 2019 Mar;74:21-28. doi: 10.1016/j.ctrv.2019.01.006. Epub 2019 Jan 19.PMID: 30685576 Free article. Review.
134. Confirmation practice in pharmacogenetic testing; how good is good enough? Lunenburg CATC, Guchelaar HJ, van Schaik RHN, Neumaier M, Swen JJ. *Clin Chim Acta.* 2019 Mar;490:77-80. doi: 10.1016/j.cca.2018.12.023. Epub 2018 Dec 21.PMID: 30582901
135. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. Andrews LM, Hesselink DA, van Schaik RHN, van Gelder T, de Fijter JW, Lloberas N, Elens L, Moes DJAR, de Winter BCM. *Br J Clin Pharmacol.* 2019 Mar;85(3):601-615. doi: 10.1111/bcp.13838. Epub 2019 Jan 17.PMID: 30552703 Free PMC article.

136. High-Frequency Biomarker Measurements of Troponin, NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute Coronary Syndrome. Oemrawsingh RM, Akkerhuis KM, de Mulder M, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, Kie The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E; BIOMarCS Investigators.Circulation. 2019 Jan 2;139(1):134-136. doi: 10.1161/CIRCULATIONAHA.118.036349.PMID: 30592652 No abstract available.
137. [Too early for pharmacogenetics in psychiatric practice? Implementation is in full swing]. van Westrhenen R, Bet PM, van Weelden M, van Schaik RHN.Tijdschr Psychiatr. 2019;61(10):678-680.PMID: 31907910 Free article. Dutch. No abstract available.
138. Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor. Epskamp C, Goudzwaard JA, Fiets E, Zuetenhorst JM, Polee MB, van de Geijn GM, van Schaik RHN, Birnie E, Hamberg P.Cancer Invest. 2019;37(3):156-162. doi: 10.1080/07357907.2019.1582660. Epub 2019 Mar 25.PMID: 30907154
139. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11.PMID: 30544060
140. Toward harmonization of clinical molecular diagnostic reports: findings of an international survey. Payne DA, Baluchova K, Russomando G, Ahmad-Nejad P, Mamotte C, Rousseau F, van Schaik RHN, Marriott K, Maekawa M, Chan KCA; IFCC Committee on Molecular Diagnostics.Clin Chem Lab Med. 2018 Dec 19;57(1):78-88. doi: 10.1515/ccm-2017-1080.PMID: 29729139 Free article.
141. Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Matejic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg J, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L, Grindedal EM, Strom SS, Neal DE, Hamdy FC, Donovan JL, Travis RC, Hamilton RJ, Rosenstein B, Lu YJ, Giles GG, Kibel AS, Vega A, Bensen JT, Kogevinas M, Penney KL, Park JY, Stanford JL, Cybulski C, Nordestgaard BG, Brenner H, Maier C, Kim J, Teixeira MR, Neuhausen SL, De Ruyck K, Razack A, Newcomb LF, Lessel D, Kaneva R, Usmani N, Claessens F, Townsend PA, Gago-Dominguez M, Roobol MJ, Menegaux F, Khaw KT, Cannon-Albright LA, Pandha H, Thibodeau SN, Schaid DJ; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Wiklund F, Chanock SJ, Easton DF, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA.Nat Commun. 2018 Nov 5;9(1):4616. doi: 10.1038/s41467-018-06863-1.PMID: 30397198 Free PMC article.
142. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM.Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.PMID: 30348537
143. Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants. van Groen BD, van de Steeg E, Mooij MG, van Lipzig MMH, de Koning BAE, Verdijk RM, Wortelboer HM, Gaedigk R, Bi C, Leeder JS, van Schaik RHN, van Rosmalen J, Tibboel D, Vaes WH, de Wildt SN.Eur J Pharm Sci. 2018 Nov 1;124:217-227. doi: 10.1016/j.ejps.2018.08.042. Epub 2018 Aug 30.PMID: 30171984 Free article.
144. CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort. Dagostino C, Allegri M, Napolioni V, D'Agnelli S, Bignami E, Mutti A, van Schaik RH.Pharmgenomics Pers Med. 2018 Oct 24;11:179-191. doi: 10.2147/PGPM.S181334. eCollection 2018.PMID: 30425549 Free PMC article.
145. Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. Verhoeven JGHP, Boer K, Van Schaik RHN, Manintveld OC, Huibers MMH, Baan CC, Hesselink DA.Ther Drug Monit. 2018 Oct;40(5):515-525. doi: 10.1097/FTD.0000000000000549.PMID: 29957668 Review.
146. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S.Clin Pharmacokinet. 2018 Oct;57(10):1229-1254. doi: 10.1007/s40262-018-0644-7.PMID: 29520731 Free PMC article. Review.
147. No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness. Koopmans AB, Vinkers DJ, Poulina IT, Gelan PJA, van Schaik RHN, Hoek HW, van Harten PN.Front Psychiatry. 2018 Aug 7;9:349. doi: 10.3389/fpsy.2018.00349. eCollection 2018.PMID: 30131727 Free PMC article.
148. Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. van Rongen A, van der Aa MP, Matic M, van Schaik RHN, Deneer VHM, van der Vorst MM, Knibbe CAJ.Paediatr Drugs. 2018 Aug;20(4):365-374. doi: 10.1007/s40272-018-0293-1.PMID: 29748932 Free PMC article. Clinical Trial.
149. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype. Haaga P, Kronstrand R, Josefsson M, Calistri S, van Schaik RHN, Green H, Kugelberg FC.Pharmacol Res Perspect. 2018 Jul 5;6(4):e00419. doi: 10.1002/prp2.419. eCollection 2018 Jul.PMID: 29992026 Free PMC article. Clinical Trial.
150. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation. Yang L, de Winter BC, van Schaik RH, Xie RX, Li Y, Andrews LM, Shuker N, Bahmani S, Koch B, van Gelder T, Hesselink DA.Pharmacogenomics. 2018 Jul 1;19(11):895-903. doi: 10.2217/pgs-2018-0066. Epub 2018 Jul 11.PMID: 29991328
151. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hökansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG. See abstract for full author list □Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11.PMID: 29892016 Free PMC article.
152. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal

variants. Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostra... See abstract for full author list [□Nat Commun.](#) 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.PMID: 29892050 Free PMC article.

153. A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT. Out M, Becker ML, van Schaik RH, Lehert P, Stehouwer CD, Kooy A. *Pharmacogenomics.* 2018 Jun 1;19(8):715-726. doi: 10.2217/pgs-2018-0010. Epub 2018 May 23.PMID: 29790415 Clinical Trial.

154. Thiopurine metabolite levels in patients with atopic dermatitis and/or chronic hand/foot eczema treated with azathioprine. Garritsen FM, van der Schaft J, Bruijnzeel-Koomen CAF, van Schaik RH, de Graaf M, van den Broek MPH, de Bruin-Weller MS. *J Dermatolog Treat.* 2018 Jun;29(4):375-382. doi: 10.1080/09546634.2017.1373738. Epub 2017 Sep 26.PMID: 28914560 Free article.

155. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. Bins S, Basak EA, El Bouazzaoui S, Koolen SLW, Oomen-de Hoop E, van der Leest CH, van der Veldt AAM, Sleijfer S, Debets R, van Schaik RHN, Aerts JGJV, Mathijssen RHJ. *Br J Cancer.* 2018 May;118(10):1296-1301. doi: 10.1038/s41416-018-0074-1. Epub 2018 Apr 26.PMID: 29695768 Free PMC article.

156. Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veeger NJ, Buunk AM, Houwink EJJ, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ; Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP). *Clin Pharmacol Ther.* 2018 May;103(5):795-801. doi: 10.1002/cpt.1049. Epub 2018 Mar 30.PMID: 29460273 Review.

157. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. *Clin Pharmacol Ther.* 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.PMID: 29385237 Free PMC article.

158. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. Andrews LM, Hesselink DA, van Gelder T, Koch BCP, Cornelissen EAM, Brüggemann RJM, van Schaik RHN, de Wildt SN, Cransberg K, de Winter BCM. *Clin Pharmacokinet.* 2018 Apr;57(4):475-489. doi: 10.1007/s40262-017-0567-8.PMID: 28681225 Free PMC article.

159. Accurate determination of the CYP2D6 (*1/*4)xN genotype by quantitative PCR. Pondman KM, van Schaik RHN, van der Weide J. *Drug Metab Pers Ther.* 2018 Mar 28;33(1):33-39. doi: 10.1515/dmpt-2017-0007.PMID: 29420304

160. A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium. Stathopoulou MG, Xie T, Ruggiero D, Chatelin J, Rancier M, Weryha G, Kurth MJ, Aldasoro Arguinano AA, Gorenjak V, Petrelis AM, Dagher G, Dedoussis G, Deloukas P, Lamont J, Marc J, Simmaco M, Schaik RHN, Innocenti F, Merlin JL, Schneider J, Alizadeh BZ, Ciullo M, Seshadri S, Visvikis-Siest S; VEGF Consortium. *Clin Chem Lab Med.* 2018 Mar 28;56(4):83-86. doi: 10.1515/cclm-2017-0838.PMID: 29087954 Free article. No abstract available.

161. Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. Lloberas N, Hesselink DA, van Schaik RH, Grinyò JM, Colom H, Gelder TV, Elens L. *Pharmacogenomics.* 2018 Mar;19(4):305-310. doi: 10.2217/pgs-2017-0301. Epub 2018 Feb 22.PMID: 29469606

162. Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpì's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. *Eur Urol* 2017;71:680-7. Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. *Eur Urol.* 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9.PMID: 28801127 No abstract available.

163. Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT). Amstutz U, Mlakar V, Curtis PH, Samer C, Baumann P, Bühlmann RP, Meier-Abt P, Meyer UA, van Schaik RHN, Ansari M; Swiss group of Pharmacogenomics and Personalised Therapy. *Drug Metab Pers Ther.* 2017 Dec 20;32(4):173-174. doi: 10.1515/dmpt-2017-0033.PMID: 29267167 Free article. No abstract available.

164. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, Kvaloy JT, Lash TL, Alnæs GIG, van Schaik RH, Janssen EAM, Hustad S, Lien EA, Mellgren G, Søiland H. *Breast Cancer Res.* 2017 Nov 28;19(1):125. doi: 10.1186/s13058-017-0916-4.PMID: 29183390 Free PMC article.

165. Treatment Algorithm for Homozygous or Compound Heterozygous DPYD Variant Allele Carriers With Low-Dose Capecitabine. Henricks LM, Kienhuis E, de Man FM, van der Veldt AAM, Hamberg P, van Kuilenburg ABP, van Schaik RHN, Lunenburg CATC, Guchelaar HJ, Schellens JHM, Mathijssen RHJ. *JCO Precis Oncol.* 2017 Nov;1:1-10. doi: 10.1200/PO.17.00118.PMID: 35172514 No abstract available.

166. Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment. Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R. *Oncotarget.* 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.PMID: 29156777 Free PMC article.

167. Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. Lammers LA, Achterbergh R, van Schaik RHN, Romijn JA, Mathôt RAA. *Clin Pharmacokinet.* 2017 Oct;56(10):1231-1244. doi: 10.1007/s40262-017-0515-7.PMID: 28229374 Free PMC article. Clinical Trial.

168. Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. Matic M, Jongen JL, Elens L, de Wildt SN, Tibboel D, Sillevius Smitt PA, van Schaik RH. *Pharmacogenomics.* 2017 Aug;18(12):1133-1142. doi: 10.2217/pgs-2017-0060. Epub 2017 Jul 26.PMID: 28745577

169. Reply. Matic M, van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RHN. *Pain.* 2017 Aug;158(8):1623. doi: 10.1097/j.pain.0000000000000945.PMID: 28715358 No abstract available.

170. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population

- Approach. Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N. *Clin Pharmacokinet*. 2017 Aug;56(8):963-975. doi: 10.1007/s40262-016-0491-3.PMID: 28050888
171. Analgesia and Opioids: A Pharmacogenetics Shortlist for Implementation in Clinical Practice. Matic M, de Wildt SN, Tibboel D, van Schaik RHN. *Clin Chem*. 2017 Jul;63(7):1204-1213. doi: 10.1373/clinchem.2016.264986.PMID: 28637770 Review.
172. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients. Oosten AW, Abrantes JA, Jönsson S, Matic M, van Schaik RHN, de Bruijn P, van der Rijt CCD, Mathijssen RHJ. *Clin Pharmacokinet*. 2017 Jul;56(7):733-746. doi: 10.1007/s40262-016-0471-7.PMID: 27815868 Free PMC article. *Clinical Trial*.
173. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ. *BJU Int*. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.PMID: 27743489 Free PMC article.
174. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Woillard JB, Mourad M, Neely M, Capron A, van Schaik RH, van Gelder T, Lloberas N, Hesselink DA, Marquet P, Haufroid V, Elens L. *Front Pharmacol*. 2017 Jun 8;8:358. doi: 10.3389/fphar.2017.00358. eCollection 2017.PMID: 28642710 Free PMC article.
175. Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype. Fattah S, Shinde AB, Matic M, Baes M, van Schaik RHN, Allegaert K, Parmentier C, Richert L, Augustijns P, Annaert P. *Pharm Res*. 2017 Jun;34(6):1309-1319. doi: 10.1007/s11095-017-2148-9. Epub 2017 Mar 31.PMID: 28364304
176. Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. Thijs JL, Van Der Geest BAM, Van Der Schaft J, Van Den Broek MP, Van Seggelen WO, Bruijnzeel-Koomen CAF, Hijnen DJ, Van Schaik RH, De Bruin-Weller MS. *J Dermatolog Treat*. 2017 May;28(3):242-245. doi: 10.1080/09546634.2016.1227420. Epub 2016 Sep 13.PMID: 27549213 Free article.
177. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R. *Eur Urol*. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10.PMID: 27733296
178. Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach. Payne DA, Baluchova K, Peoc'h KH, van Schaik RHN, Chan KCA, Maekawa M, Mamotte C, Russomando G, Rousseau F, Ahmad-Nejad P; IFCC Committee for Molecular Diagnostics (C-MD). *Clin Chim Acta*. 2017 Apr;467:59-69. doi: 10.1016/j.cca.2016.06.018. Epub 2016 Jun 16.PMID: 27321365
179. Correction: A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. Mizzi C, Dalabira E, Kumuthini J, Dzimir N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši L, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Sertić J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, McLeod HL, van der Spek PJ, Patrinos GP. *PLoS One*. 2017 Feb 16;12(2):e0172595. doi: 10.1371/journal.pone.0172595. eCollection 2017.PMID: 28207884 Free PMC article.
180. Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. Andrews LM, de Winter BC, Tang JT, Shuker N, Bouamar R, van Schaik RH, Koch BC, van Gelder T, Hesselink DA. *Transplant Direct*. 2017 Jan 19;3(2):e129. doi: 10.1097/TXD.0000000000000644. eCollection 2017 Feb.PMID: 28361113 Free PMC article.
181. Performance Ratio Based Resource Allocation Decision-Making in Genomic Medicine. Fragoulakis V, Mitropoulou C, Katelidou D, van Schaik RH, Maniadas N, Patrinos GP. *OMICS*. 2017 Feb;21(2):67-73. doi: 10.1089/omi.2016.0161. Epub 2017 Jan 24.PMID: 28118098
182. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. Zhu L, Brüggemann RJ, Uy J, Colbers A, Hruska MW, Chung E, Sims K, Vakkalagadda B, Xu X, van Schaik RH, Burger DM, Bertz RJ. *J Clin Pharmacol*. 2017 Feb;57(2):235-246. doi: 10.1002/jcph.798. Epub 2016 Aug 23.PMID: 27432796
183. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease. Baggen VJ, van den Bosch AE, Eindhoven JA, Schut AW, Cuypers JA, Witsenburg M, de Waart M, van Schaik RH, Zijlstra F, Boersma E, Roos-Hesselink JW. *Circulation*. 2017 Jan 17;135(3):264-279. doi: 10.1161/CIRCULATIONAHA.116.023255. Epub 2016 Nov 3.PMID: 27832613
184. Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, van Kuilenburg ABP. *Ann Oncol*. 2017 Jan 1;28(1):183. doi: 10.1093/annonc/mdw448.PMID: 27687313 Free article. No abstract available.
185. Cohort profile of BIOMARCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome—a prospective multicentre biomarker study conducted in the Netherlands. Oemrawsingh RM, Akkerhuis KM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, Lenderink T, Liem A, Haitisma D, van der Harst P, Asselbergs FW, Maas A, Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, The SH, Wardeh AJ, Hermans W, Cramer E, van Schaik RH, Hofer IE, Doevendans PA, Simoons ML, Boersma E. *BMJ Open*. 2016 Dec 23;6(12):e012929. doi: 10.1136/bmjopen-2016-012929.PMID: 28011810 Free PMC article.
186. Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Mitropoulou C, Fragoulakis V, Rakicevic LB, Novkovic MM, Vozikis A, Matic DM, Antonijevic NM, Radojkovic DP, van Schaik RH, Patrinos GP. *Pharmacogenomics*. 2016 Nov;17(16):1775-1784. doi: 10.2217/pgs-2016-0052. Epub 2016 Oct 21.PMID: 27767438
187. Implication of UGT2B15 Genotype Polymorphism on Postoperative Anxiety Levels in Patients Receiving Lorazepam Premedication. Mijderwijk H, Klimek M, van Beek S, van Schaik RH, Duivenvoorden HJ, Stolker RJ. *Anesth Analg*. 2016 Nov;123(5):1109-1115. doi: 10.1213/ANE.0000000000001508.PMID: 27622723 *Clinical Trial*.
188. Genetic variants associated with thermal pain sensitivity in a paediatric population. Matic M, van den Bosch GE, de Wildt SN, Tibboel D, van Schaik RHN. *Pain*. 2016 Nov;157(11):2476-2482. doi: 10.1097/j.pain.0000000000000664.PMID: 27541715
189. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH. *Pharmacogenomics J*. 2016 Nov;16(6):519-524. doi: 10.1038/tj.2015.66. Epub 2015 Sep 8.PMID: 26345519
190. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. Mizzi C, Dalabira E, Kumuthini J, Dzimir N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši L, Kučinskas

V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, McLeod HL, van der Spek PJ, Patrinos GP. *PLoS One*. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. PMID: 27636550 Free PMC article.

191. Minimum information required for a DMET experiment reporting. Kumuthini J, Mbiyavanga M, Chimusa ER, Pathak J, Somervuo P, Van Schaik RH, Dolzan V, Mizzi C, Kalideen K, Ramesar RS, Macek M, Patrinos GP, Squassina A. *Pharmacogenomics*. 2016 Sep;17(14):1533-45. doi: 10.2217/pgs-2016-0015. Epub 2016 Aug 22. PMID: 27548815 Free PMC article.

192. Polymorphisms in SLC01B1 and UGT1A1 are associated with sorafenib-induced toxicity. Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH. *Pharmacogenomics*. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17. PMID: 27533851

193. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židžik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RHN, Stehouwer CDA, Logie L; MetGen Investigators; DPP Investigators; ACCORD Investigators; Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, Innocenti F, 't Hart LM, Holman RR, McCarthy MI, Hedderon MM, Palmer CNA, Florez JC, Giacomini KM, Pearson ER. *Nat Genet*. 2016 Sep;48(9):1055-1059. doi: 10.1038/ng.3632. Epub 2016 Aug 8. PMID: 27500523 Free PMC article.

194. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Prytula AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, Mathôt RA. *Clin Pharmacokinet*. 2016 Sep;55(9):1129-43. doi: 10.1007/s40262-016-0390-7. PMID: 27138785

195. The Effect of Roux-en-Y Gastric Bypass Surgery in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid and Omeprazole: the ERY-PAO Study. Mitrov-Winkelmoelen L, van Buul-Gast MW, Swank DJ, Overdiek HWPM, van Schaik RHN, Touw DJ. *Obes Surg*. 2016 Sep;26(9):2051-2058. doi: 10.1007/s11695-016-2065-8. PMID: 26797705 Clinical Trial.

196. Opioid treatment failure in cancer patients: the role of clinical and genetic factors. Oosten AW, Matic M, van Schaik RH, Look MP, Jongen JL, Mathijssen RH, van der Rijt CC. *Pharmacogenomics*. 2016 Aug;17(13):1391-403. doi: 10.2217/pgs-2016-0082. Epub 2016 Jul 29. PMID: 27472837

197. Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome. Teeninga N, Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ, van Schaik RH, van Gelder T, Nauta J. *Ther Drug Monit*. 2016 Aug;38(4):534-45. doi: 10.1097/FTD.0000000000000308. PMID: 27120177 Clinical Trial.

198. SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Matic M, de Wildt SN, Elens L, de Hoon JN, Annaert P, Tibboel D, van Schaik RH, Allegaert K. *Ther Drug Monit*. 2016 Aug;38(4):487-92. doi: 10.1097/FTD.0000000000000307. PMID: 27082504

199. Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation. Elens L, Norman E, Matic M, Rane A, Fellman V, van Schaik RH. *Ther Drug Monit*. 2016 Aug;38(4):525-33. doi: 10.1097/FTD.0000000000000301. PMID: 27027462

200. Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. Vet NJ, Brussee JM, de Hoog M, Mooij MG, Verlaet CW, Jerchel IS, van Schaik RH, Koch BC, Tibboel D, Knibbe CA, de Wildt SN; SKIC (Dutch collaborative PICU research network). *Am J Respir Crit Care Med*. 2016 Jul 1;194(1):58-66. doi: 10.1164/rccm.201510-2114OC. PMID: 26796541 Clinical Trial.

201. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. Shuker N, Bouamar R, van Schaik RH, Clahsen-van Groningen MC, Damman J, Baan CC, van de Wetering J, Rowshani AT, Weimar W, van Gelder T, Hesselink DA. *Am J Transplant*. 2016 Jul;16(7):2085-96. doi: 10.1111/ajt.13691. Epub 2016 Feb 26. PMID: 26714287 Free article. Clinical Trial.

202. An Alternative Methodological Approach for Cost-Effectiveness Analysis and Decision Making in Genomic Medicine. Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadas N, Patrinos GP. *OMICS*. 2016 May;20(5):274-82. doi: 10.1089/omi.2016.0018. Epub 2016 Apr 20. PMID: 27096406

203. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? Del Re M, Citi V, Crucitta S, Rofi E, Belcari F, van Schaik RH, Danesi R. *Pharmacol Res*. 2016 May;107:398-406. doi: 10.1016/j.phrs.2016.03.025. Epub 2016 Apr 8. PMID: 27060675 Review.

204. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Tang JT, Andrews LM, van Gelder T, Shi YY, van Schaik RH, Wang LL, Hesselink DA. *Expert Opin Drug Metab Toxicol*. 2016 May;12(5):555-65. doi: 10.1517/17425255.2016.1170808. Epub 2016 Apr 7. PMID: 27010623 Free article. Review.

205. High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study. Oemrawsingh RM, Cheng JM, García-García HM, Kardys I, van Schaik RH, Regar E, van Geuns RJ, Serruys PW, Boersma E, Akkerhuis KM. *Atherosclerosis*. 2016 Apr;247:135-41. doi: 10.1016/j.atherosclerosis.2016.02.012. Epub 2016 Feb 15. PMID: 26917225 Free article.

206. Elevated Plasma Cardiac Troponin T Levels Caused by Skeletal Muscle Damage in Pompe Disease. Wens SC, Schaaf GJ, Michels M, Kruijshaar ME, van Gestel TJ, In 't Groen S, Pijnenburg J, Dekkers DH, Demmers JA, Verdijk LB, Brussee E, van Schaik RH, van der Ploeg AT, van Doorn PA, Pijnappel WW. *Circ Cardiovasc Genet*. 2016 Feb;9(1):6-13. doi: 10.1161/CIRCGENETICS.115.001322. Epub 2016 Jan 19. PMID: 26787432

207. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, Innocenti F. *Pharmacogenomics J*. 2016 Feb;16(1):54-9. doi: 10.1038/tpj.2015.23. Epub 2015 Apr 14. PMID: 25869015 Free PMC article.

208. Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Vozizik A, Cooper DN, Mitropoulou C, Kambouris ME, Brand A, Dolzan V, Fortina P, Innocenti F, Lee MT, Leyens L, Macek M Jr, Al-Mulla F, Prainsack B, Squassina A, Taruscio D, van Schaik RH, Vayena E, Williams MS, Patrinos GP. *Public Health Genomics*. 2016;19(6):352-363. doi: 10.1159/000449152. Epub 2016 Sep 28. PMID: 27676083 Free article. Review.

209. First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding. van der Schaft J, van Schaik RH, van Zuijlen AD, Hijnen DJ, Berg MT, van den Broek MP, Bruijnzeel-Koomen CA, de Bruin-Weller MS. *J Dermatol Sci*. 2016 Jan;81(1):66-8. doi: 10.1016/j.jdermsci.2015.10.013. Epub 2015 Oct 28. PMID: 26547110 No abstract available.

210. Release of growth-differentiation factor 15 and associations with cardiac function in adult patients with congenital heart disease. Eindhoven JA, van den Bosch AE, Oemrawsingh RM, Baggen VJ, Kardys I, Cuyppers JA, Witsenburg M, van Schaik RH, Roos-Hesselink JW, Boersma E. *Int J Cardiol*. 2016 Jan 1;202:246-51. doi:

10.1016/j.ijcard.2015.09.010. Epub 2015 Sep 14.PMID: 26402453

211. Pharmacokinetic drug-drug interaction study between raltegravir and citalopram. Blonk MI, Langemeijer CC, Colbers AP, Hoogtanders KE, van Schaik RH, Schouwenberg BJ, Burger DM. *Antivir Ther*. 2016;21(2):143-52. doi: 10.3851/IMP2993. Epub 2015 Sep 16.PMID: 26375942 Clinical Trial.
212. Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Weigel JD, Hunfeld NG, Koch BC, Egal M, Bakker J, van Schaik RH, van Gelder T. *Intensive Care Med*. 2015 Nov;41(11):2013-4. doi: 10.1007/s00134-015-4002-z. Epub 2015 Aug 4.PMID: 26239729 No abstract available.
213. Increased liver enzyme levels during azathioprine treatment: beware of concomitant use of proton pump inhibitors. van der Schaft J, van Schaik RH, van den Broek MP, Bruijnzeel-Koomen CA, de Bruin-Weller MS. *Br J Dermatol*. 2015 Nov;173(5):1338-9. doi: 10.1111/bjd.14006. Epub 2015 Oct 13.PMID: 26139089 No abstract available.
214. 4 β -hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. *Br J Clin Pharmacol*. 2015 Sep;80(3):560-8. doi: 10.1111/bcp.12707. Epub 2015 Aug 12.PMID: 26119961 Free PMC article. Clinical Trial.
215. The Effect of Tamoxifen Dose Increment in Patients With Impaired CYP2D6 Activity. Welzen ME, Dezentjé VO, van Schaik RH, Colbers AP, Guchelaar HJ, van Erp NP, den Hartigh J, Burger DM, van Laarhoven HW. *Ther Drug Monit*. 2015 Aug;37(4):501-7. doi: 10.1097/FTD.0000000000000195.PMID: 26192892 Clinical Trial.
216. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients. Binkhorst L, Kloth JSL, de Wit AS, de Bruijn P, Lam MH, Chaves I, Burger H, van Alphen RJ, Hamberg P, van Schaik RHN, Jager A, Koch BCP, Wiemer EAC, van Gelder T, van der Horst GTJ, Mathijssen RH. *Breast Cancer Res Treat*. 2015 Jul;152(1):119-128. doi: 10.1007/s10549-015-3452-x. Epub 2015 Jun 7.PMID: 26050156 Free PMC article.
217. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J, van Schaik RH, Siest G, Theodorsson E, Pazzagli M, Di Resta C; European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) – European Society of Pharmacogenomics and Personalised Therapy (ESPT) Joint Working Group on Personalized Laboratory Medicine (WG-PLM). *Drug Metab Pers Ther*. 2015 Jun;30(2):121-8. doi: 10.1515/dmdi-2015-0012.PMID: 26036226 Free article.
218. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe. Malentacchi F, Mancini I, Brandslund I, Vermeersch P, Schwab M, Marc J, van Schaik RH, Siest G, Theodorsson E, Pazzagli M, Di Resta C; European Federation of Clinical Chemistry and Laboratory Medicine (EFLM); European Society of Pharmacogenomics and Personalised Therapy (ESPT) Joint Working Group on Personalized Laboratory Medicine (WG-PLM). *Clin Chem Lab Med*. 2015 Jun;53(7):981-8. doi: 10.1515/ccim-2015-0171.PMID: 25995323 Free article.
219. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. *Prostate Cancer Prostatic Dis*. 2015 Jun;18(2):167-72. doi: 10.1038/pcan.2015.8. Epub 2015 Mar 10.PMID: 25753371
220. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy. Kraff S, Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, Jaehde U, Joerger M. *Cancer Chemother Pharmacol*. 2015 May;75(5):975-83. doi: 10.1007/s00280-015-2724-9. Epub 2015 Mar 12.PMID: 25761456
221. Association of CYP3A variants with kidney transplant outcomes. Traynor C, Conlon P Jr, Phelan PJ, O'Kelly P, Elens L, McCormack M, Cavalleri G, Comber H, van Schaik RH, Conlon PJ. *Ren Fail*. 2015 May;37(4):562-6. doi: 10.3109/0886022X.2015.1007013. Epub 2015 Feb 3.PMID: 25644970 Free article.
222. High-sensitive troponin-T in adult congenital heart disease. Eindhoven JA, Roos-Hesselink JW, van den Bosch AE, Kardys I, Cheng JM, Veenis JF, Cuypers JAAE, Witsenburg M, van Schaik RHN, Boersma E. *Int J Cardiol*. 2015 Apr 1;184:405-411. doi: 10.1016/j.ijcard.2015.02.027. Epub 2015 Feb 25.PMID: 25746495
223. The prostate health index selectively identifies clinically significant prostate cancer. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. *J Urol*. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15.PMID: 25463993 Free PMC article.
224. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. de Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DR. *Pharmacogenomics J*. 2015 Apr;15(2):144-52. doi: 10.1038/tpj.2014.49. Epub 2014 Oct 7.PMID: 25287072
225. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. *Drug Metab Pers Ther*. 2015 Mar;30(1):43-8. doi: 10.1515/dmdi-2014-0021.PMID: 25274942
226. Systems medicine, personalized health and therapy. Siest G, Auffray C, Taniguchi N, Ingelman-Sundberg M, Murray H, Visvikis-Siest S, Ansari M, Marc J, Jacobs P, Meyer U, Van Schaik RH, Müller MM, Wevers RA, Simmaco M, Kussmann M, Manolopoulos VG, Alizadeh BZ, Beastall G, Németh G. *Pharmacogenomics*. 2015;16(14):1527-39. doi: 10.2217/pgs.15.103. Epub 2015 Sep 24.PMID: 26401575
227. Predicting paclitaxel-induced neutropenia using the DMET platform. Nieuweboer AJ, Smid M, de Graan AJ, Elbouazzaoui S, de Bruijn P, Martens JW, Mathijssen RH, van Schaik RH. *Pharmacogenomics*. 2015;16(11):1231-41. doi: 10.2217/pgs.15.68. Epub 2015 Aug 12.PMID: 26265135
228. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke. Mitropoulou C, Fragoulakis V, Bozina N, Vozikis A, Supe S, Bozina T, Poljakovic Z, van Schaik RH, Patrinos GP. *Pharmacogenomics*. 2015 Jan;16(2):137-48. doi: 10.2217/pgs.14.167.PMID: 25616100 Clinical Trial.
229. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Mänttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators. *Lancet*. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.PMID: 25108889 Free PMC article. Clinical Trial.
230. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Drogari E, Ragia G, Mollaki V, Elens L, Van Schaik RH, Manolopoulos VG. *Pharmacogenomics*. 2014 Dec;15(16):1963-72. doi: 10.2217/pgs.14.138.PMID: 25521355
231. MAOA, COMT and 5-HTTLPR frequencies in convicted and never convicted Afro-Caribbeans in the

- Netherlands. Vinkers DJ, Bogaerts S, Van Schaik RH. *Crim Behav Ment Health*. 2014 Dec;24(5):365-7. doi: 10.1002/cbm.1908.PMID: 25510658 No abstract available.
232. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. van Gelder T, van Schaik RH, Hesselink DA. *Nat Rev Nephrol*. 2014 Dec;10(12):725-31. doi: 10.1038/nrneph.2014.172. Epub 2014 Sep 23.PMID: 25247332 Review.
233. Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? Li P, Shuker N, Hesselink DA, van Schaik RH, Zhang X, van Gelder T. *Transpl Int*. 2014 Oct;27(10):994-1004. doi: 10.1111/tri.12382. Epub 2014 Aug 22.PMID: 24963914 Free article. Review.
234. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation. Tapirdamaz Ö, Hesselink DA, el Bouazzaoui S, Azimpour M, Hansen B, van der Laan LJ, Polak WG, Kwekkeboom J, van Schaik RH, van Gelder T, Metselaer HJ. *Pharmacogenet Genomics*. 2014 Sep;24(9):427-35. doi: 10.1097/FPC.000000000000063.PMID: 25014506
235. No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction. Leusink M, de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, de Boer A, van Schaik RH, Maitland-van der Zee AH. *Pharmacogenomics*. 2014 Aug;15(11):1471-7. doi: 10.2217/pgs.14.90.PMID: 25303298
236. Using tramadol to measure CYP2D6 metabolism in critically ill adults. Lane K, Dixon JJ, McKeown D, Johnston A, van Schaik RH, van Fessem M, MacPhee IA, Philips BJ. *Intensive Care Med*. 2014 Aug;40(8):1177-8. doi: 10.1007/s00134-014-3372-y. Epub 2014 Jun 27.PMID: 24968714 No abstract available.
237. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Matic M, Simons SH, van Lingen RA, van Rosmalen J, Elens L, de Wildt SN, Tibboel D, van Schaik RH. *Pharmacogenomics*. 2014 Jul;15(10):1287-95. doi: 10.2217/pgs.14.100.PMID: 25155931 Clinical Trial.
238. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Diekstra MH, Klümper HJ, Lolkema MP, Yu H, Kloth JS, Gelderblom H, van Schaik RH, Gurney H, Swen JJ, Huitema AD, Steeghs N, Mathijssen RH. *Clin Pharmacol Ther*. 2014 Jul;96(1):81-9. doi: 10.1038/clpt.2014.47. Epub 2014 Feb 24.PMID: 24566734
239. Calcineurin inhibitors and hypertension: a role for pharmacogenetics? Moes AD, Hesselink DA, Zietse R, van Schaik RH, van Gelder T, Hoorn EJ. *Pharmacogenomics*. 2014 Jun;15(9):1243-51. doi: 10.2217/pgs.14.87.PMID: 25141899 Review.
240. Personalized pharmacogenomics profiling using whole-genome sequencing. Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, van Schaik RH, Drmanac R, Borg J, Patrinos GP. *Pharmacogenomics*. 2014 Jun;15(9):1223-34. doi: 10.2217/pgs.14.102.PMID: 25141897
241. Genetic polymorphisms in IL-2, IL-10, TGF-β1, and IL-2RB and acute rejection in renal transplant patients. Chen Z, Bouamar R, Van Schaik RH, De Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Weimar W, Hesselink DA, Van Gelder T. *Clin Transplant*. 2014 Jun;28(6):649-55. doi: 10.1111/ctr.12346. Epub 2014 Jun 3.PMID: 24579958
242. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. *Mol Diagn Ther*. 2014 Jun;18(3):323-31. doi: 10.1007/s40291-013-0082-z.PMID: 24430948
243. Key challenges for next-generation pharmacogenomics: Science & Society series on Science and Drugs. Kampourakis K, Vayena E, Mitropoulou C, van Schaik RH, Cooper DN, Borg J, Patrinos GP. *EMBO Rep*. 2014 May;15(5):472-6. doi: 10.1002/embr.201438641. Epub 2014 Apr 10.PMID: 24723683 Free PMC article. No abstract available.
244. Conference scene: pharmacogenomics: from cell to clinic (part 2). Siest G, Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. *Pharmacogenomics*. 2014 Apr;15(6):739-44. doi: 10.2217/pgs.14.36.PMID: 24897282
245. Pharmacogenomics: from cell to clinic (Part 1). Siest G, Medeiros R, Melichar B, Stathopoulou M, Van Schaik RH, Cacabelos R, Abt PM, Monteiro C, Gurwitz D, Queiroz J, Mota-Filipe H, Ndiaye NC, Visvikis-Siest S. *Pharmacogenomics*. 2014 Apr;15(5):593-9. doi: 10.2217/pgs.14.35.PMID: 24798716
246. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Elens L, Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RH. *Br J Clin Pharmacol*. 2014 Apr;77(4):715-28. doi: 10.1111/bcp.12253.PMID: 24118098 Free PMC article. Review.
247. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients—a pilot study. Gijsen VM, van Schaik RH, Soldin OP, Soldin SJ, Nulman I, Koren G, de Wildt SN. *Ther Drug Monit*. 2014 Apr;36(2):152-8. doi: 10.1097/FTD.0b013e3182a3f282.PMID: 24089076
248. Practicability of pharmacogenetics in transplantation medicine. van Gelder T, van Schaik RH, Hesselink DA. *Clin Pharmacol Ther*. 2014 Mar;95(3):262-4. doi: 10.1038/clpt.2013.169. Epub 2013 Aug 29.PMID: 23995265 Review.
249. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. *Clin Pharmacokinet*. 2014 Feb;53(2):123-39. doi: 10.1007/s40262-013-0120-3.PMID: 24249597 Review.
250. Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. van der Pas R, van Esch JH, de Bruin C, Danser AH, Pereira AM, Zelissen PM, Netea-Maier R, Sprij-Mooij DM, van den Berg-Garrelts IM, van Schaik RH, Lamberts SW, van den Meiracker AH, Hofland LJ, Feelders RA. *Eur J Endocrinol*. 2014 Feb 1;170(2):181-91. doi: 10.1530/EJE-13-0477. Print 2014 Feb.PMID: 24165019
251. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH. *Ther Drug Monit*. 2014 Feb;36(1):71-9. doi: 10.1097/FTD.0b013e31829da6dd.PMID: 24061445 Clinical Trial.
252. Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Mai Y, Mitropoulou C, Papadopoulou XE, Vozikis A, Cooper DN, van Schaik RH, Patrinos GP. *Per Med*. 2014 Jan;11(1):15-26. doi: 10.2217/pme.13.92.PMID: 29751393
253. Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Matic M, Norman E, Rane A, Beck O, Andersson M, Elens L, Tibboel D, Fellman V, van Schaik RH. *Pharmacogenomics*. 2014;15(12):1589-97. doi: 10.2217/pgs.14.115.PMID: 25340733
254. Stakeholder analysis in pharmacogenomics and genomic medicine in Greece. Mitropoulou C, Mai Y, van Schaik RH, Vozikis A, Patrinos GP. *Public Health Genomics*. 2014;17(5-6):280-6. doi: 10.1159/000365896. Epub

2014 Sep 9.PMID: 25228172

255. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas. Ragia G, Tavridou A, Elens L, Van Schaik RH, Manolopoulos VG. *Exp Clin Endocrinol Diabetes*. 2014 Jan;122(1):60-3. doi: 10.1055/s-0033-1361097. Epub 2014 Jan 24.PMID: 24464600
256. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Dezentjé VO, Gelderblom H, Van Schaik RH, Vletter-Bogaartz JM, Van der Straaten T, Wessels JA, Kranenborg EM, Berns EM, Seynaeve C, Putter H, Van de Velde CJ, Nortier JW, Guchelaar HJ. *Breast Cancer Res Treat*. 2014 Jan;143(1):171-9. doi: 10.1007/s10549-013-2777-6. Epub 2013 Nov 22.PMID: 24265036
257. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, Schellens JH, Linn SC, Beijnen JH. *BMC Cancer*. 2013 Dec 28;13:612. doi: 10.1186/1471-2407-13-612.PMID: 24373320 Free PMC article.
258. Time of injury affects urinary biomarker predictive values for acute kidney injury in critically ill, non-septic patients. de Geus HR, Fortrie G, Betjes MG, van Schaik RH, Groeneveld AB. *BMC Nephrol*. 2013 Dec 9;14:273. doi: 10.1186/1471-2369-14-273.PMID: 24321290 Free PMC article.
259. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor- α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Elens L, Sombogaard F, Hesselink DA, van Schaik RH, van Gelder T. *Pharmacogenet Genomics*. 2013 Dec;23(12):649-57. doi: 10.1097/FPC.0000000000000001.PMID: 24113216
260. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V. *Ther Drug Monit*. 2013 Oct;35(5):608-16. doi: 10.1097/FTD.0b013e318296045b.PMID: 24052064
261. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group. *Eur Urol*. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.PMID: 23759326 Clinical Trial.
262. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, Friberg LE, Elbouazzaoui S, Wiemer EA, van der Holt B, Verweij J, van Schaik RH, Mathijssen RH. *Clin Cancer Res*. 2013 Sep 15;19(18):5210-7. doi: 10.1158/1078-0432.CCR-13-0487. Epub 2013 Aug 5.PMID: 23918604
263. Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. de Keyser CE, Becker ML, Uitterlinden AG, Hofman A, Lous JJ, Elens L, Visser LE, van Schaik RH, Stricker BH. *Pharmacogenomics*. 2013 Aug;14(11):1295-304. doi: 10.2217/pgs.13.112.PMID: 23930676
264. Association between genetic variation in the ABCB1 gene and switching, discontinuation, and dosage of antidepressant therapy: results from the Rotterdam Study. Noordam R, Aarts N, Hofman A, van Schaik RH, Stricker BH, Visser LE. *J Clin Psychopharmacol*. 2013 Aug;33(4):546-50. doi: 10.1097/JCP.0b013e318291c07b.PMID: 23771194
265. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Vafadari R, Bouamar R, Hesselink DA, Kraaijeveld R, van Schaik RH, Weimar W, Baan CC, van Gelder T. *Ther Drug Monit*. 2013 Aug;35(4):459-65. doi: 10.1097/FTD.0b013e31828c1581.PMID: 23743668
266. Sex difference in formation of propofol metabolites: a replication study. Choong E, Loryan I, Lindqvist M, Nordling Å, el Bouazzaoui S, van Schaik RH, Johansson I, Jakobsson J, Ingelman-Sundberg M. *Basic Clin Pharmacol Toxicol*. 2013 Aug;113(2):126-31. doi: 10.1111/bcpt.12070. Epub 2013 May 20.PMID: 23527701 Free article.
267. CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. Dezentjé VO, van Schaik RH, Vletter-Bogaartz JM, van der Straaten T, Wessels JA, Kranenborg EM, Berns EM, Seynaeve C, Putter H, van de Velde CJ, Nortier JW, Gelderblom H, Guchelaar HJ. *Breast Cancer Res Treat*. 2013 Jul;140(2):363-73. doi: 10.1007/s10549-013-2619-6. Epub 2013 Jul 11.PMID: 23842856 Clinical Trial.
268. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Gijsen VM, van Schaik RH, Elens L, Soldin OP, Soldin SJ, Koren G, de Wildt SN. *Pharmacogenomics*. 2013 Jul;14(9):1027-36. doi: 10.2217/pgs.13.80.PMID: 23837477
269. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. *Clin Cancer Res*. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2.PMID: 23640974 Free PMC article.
270. CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC. *Breast Cancer Res Treat*. 2013 Jun;139(3):649-55. doi: 10.1007/s10549-013-2568-0. Epub 2013 Jun 5.PMID: 23736997 Free PMC article. Clinical Trial.
271. The Val158Met polymorphism of the COMT gene is associated with increased pain sensitivity in morphine-treated patients undergoing a painful procedure after cardiac surgery. Ahlers SJ, Elens LL, van Gulik L, van Schaik RH, van Dongen EP, Bruins P, Tibboel D, Knibbe CA. *Br J Clin Pharmacol*. 2013 Jun;75(6):1506-15. doi: 10.1111/bcp.12052.PMID: 23210659 Free PMC article.
272. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Elens L, Hesselink DA, van Schaik RH, van Gelder T. *Br J Clin Pharmacol*. 2013 Jun;75(6):1545-7. doi: 10.1111/bcp.12038.PMID: 23163400 Free PMC article. No abstract available.
273. Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. Becker ML, Elens LL, Visser LE, Hofman A, Uitterlinden AG, van Schaik RH, Stricker BH. *Pharmacogenomics J*. 2013 Jun;13(3):251-6. doi: 10.1038/tpj.2011.59. Epub 2011 Dec 20.PMID: 22186618
274. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, van Schaik RH. *J Pain Res*. 2013 May 1;6:331-53. doi: 10.2147/JPR.S42040. Print 2013.PMID: 23658496 Free PMC article.
275. Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ. *J Urol*. 2013 May;189(5):1702-6. doi: 10.1016/j.juro.2012.11.149. Epub 2012 Nov 30.PMID: 23206426 Free PMC article.
276. A clinical approach to pharmacogenetics. de Graaff LC, van Schaik RH, van Gelder T. *Neth J Med*. 2013

Apr;71(3):145-52.PMID: 23712814 Free article.

277. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam. Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW. *Eur Urol*. 2013 Apr;63(4):627-33. doi: 10.1016/j.eururo.2012.07.029. Epub 2012 Jul 20. PMID: 22841675

278. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Elens L, Nieuweboer AJ, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, van Gelder T, Mathijssen RH, van Schaik RH. *Pharmacogenet Genomics*. 2013 Mar;23(3):148-55. doi: 10.1097/FPC.0b013e32835dc113. PMID: 23324807

279. Doubt about the feasibility of preemptive genotyping. Koch BC, van Schaik RH, van Gelder T, Mathijssen RH; Rotterdam Clinical Pharmacology-Pharmacogenetics Group (RCPPG). *Clin Pharmacol Ther*. 2013 Mar;93(3):233. doi: 10.1038/clpt.2012.191. Epub 2012 Dec 12. PMID: 23232547 No abstract available.

280. Clinical Application of Pharmacogenetics: Where are We Now? van Schaik RH; IFCC Task Force on Pharmacogenetics: Prof. Dr. Maurizio Ferrari (IT), Prof. Dr. Michael Neumaier (GER), Prof. Dr. Munir Pirmohamed (UK), Prof. Dr. Henk-Jan Guchelaar (NL), Prof. Dr. Ron van Schaik (NL). *EJIFCC*. 2013 Feb 21;24(3):105-12. eCollection 2013 Feb. PMID: 27683445 Free PMC article.

281. New challenges for pharmacogenomics. van Schaik RH. *Drug Metabol Drug Interact*. 2013;28(4):191-2. doi: 10.1515/dmdi-2013-0060. PMID: 24361773 No abstract available.

282. Evidence based drug dosing and pharmacotherapeutic recommendations per genotype. Deneer VH, van Schaik RH. *Methods Mol Biol*. 2013;1015:345-54. doi: 10.1007/978-1-62703-435-7_23. PMID: 23824868

283. A guide to the current Web-based resources in pharmacogenomics. Glubb DM, Paugh SW, van Schaik RH, Innocenti F. *Methods Mol Biol*. 2013;1015:293-310. doi: 10.1007/978-1-62703-435-7_19. PMID: 23824864 Free PMC article.

284. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH. *Pharmacogenomics*. 2013 Jan;14(2):137-49. doi: 10.2217/pgs.12.202. PMID: 23327575

285. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Elens L, van Gelder T, Hesselink DA, Haufroid V, van Schaik RH. *Pharmacogenomics*. 2013 Jan;14(1):47-62. doi: 10.2217/pgs.12.187. PMID: 23252948 Review.

286. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. Elens L, Hesselink DA, van Schaik RH, van Gelder T. *Mol Diagn Ther*. 2012 Dec;16(6):331-45. doi: 10.1007/s40291-012-0012-5. PMID: 23192462 Review.

287. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. de Rotte MC, Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, Wulffraat NM, de Jonge R. *J Rheumatol*. 2012 Oct;39(10):2032-40. doi: 10.3899/jrheum.111593. Epub 2012 Aug 1. PMID: 22859359

288. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Shuker N, Bouamar R, Weimar W, van Schaik RH, van Gelder T, Hesselink DA. *Clin Chim Acta*. 2012 Sep 8;413(17-18):1326-37. doi: 10.1016/j.cca.2011.09.040. Epub 2011 Oct 5. PMID: 21996082 Review.

289. Multi-center analytical performance evaluation of the Access Hybritech® p2PSA immunoassay. Sokoll LJ, Chan DW, Klee GG, Roberts WL, van Schaik RH, Arockiasamy DA, Broyles DL, Carlson CM, Mizrahi IA, Pierson TB, Tam JE. *Clin Chim Acta*. 2012 Aug 16;413(15-16):1279-83. doi: 10.1016/j.cca.2012.04.015. Epub 2012 Apr 20. PMID: 22542565

290. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A. *Clin Cancer Res*. 2012 Aug 15;18(16):4433-40. doi: 10.1158/1078-0432.CCR-12-0761. Epub 2012 Jun 18. PMID: 22711709 Free PMC article.

291. Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. Mutwa PR, Fillekes Q, Malgaz M, Tuyishimire D, Kraats Rv, Boer KR, Burger DM, van Schaik RH, Muganga N, Geelen SP. *J Acquir Immune Defic Syndr*. 2012 Aug 1;60(4):400-4. doi: 10.1097/QAI.0b013e3182569f57. PMID: 22481606

292. Effects of CYP induction by rifampicin on tamoxifen exposure. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH. *Clin Pharmacol Ther*. 2012 Jul;92(1):62-7. doi: 10.1038/clpt.2011.372. Epub 2012 May 23. PMID: 22617226 Clinical Trial.

293. 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. van Dijk SC, de Herder WW, Kwekkeboom DJ, Zillikens MC, Feelders RA, van Schaik RH, van Driel M, van Leeuwen JP. *Bone*. 2012 Jun;50(6):1260-5. doi: 10.1016/j.bone.2012.02.637. Epub 2012 Mar 8. PMID: 22425693

294. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, van der Heiden IP, de Fijter JW, Kuypers DR, van Gelder T. *Pharmacogenet Genomics*. 2012 Jun;22(6):399-407. doi: 10.1097/FPC.0b013e32834a8650. PMID: 21878834 Clinical Trial.

295. Mycophenolic acid-related anemia and leucopenia in renal transplant recipients are related to genetic polymorphisms in CYP2C8. Bouamar R, Elens L, Shuker N, van Schaik RH, Weimar W, Hesselink DA, van Gelder T. *Transplantation*. 2012 May 27;93(10):e39-40; author reply e41-2. doi: 10.1097/TP.0b013e3182488bb4. PMID: 22572835 No abstract available.

296. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. *Pharmacogenet Genomics*. 2012 May;22(5):373-80. doi: 10.1097/FPC.0b013e328351f3c1. PMID: 22388796

297. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases. Piana C, Surh L, Furst-Recktenwald S, Iolascon A, Jacqz-Aigrain EM, Jonker I, Russo R, van Schaik RH, Wessels J, Della Pasqua OE. *J Clin Pharmacol*. 2012 May;52(5):704-16. doi: 10.1177/0091270011401619. Epub 2011 May 12. PMID: 21566202 Review.

298. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH. *Ther Drug Monit*. 2012 Apr;34(2):153-9. doi: 10.1097/FTD.0b013e31824868f3. PMID: 22354160

299. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. *Aliment Pharmacol Ther*.

- 2012 Apr;35(7):810-8. doi: 10.1111/j.1365-2036.2012.05014.x. Epub 2012 Feb 13.PMID: 22324425 Clinical Trial.
300. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. *Eur J Clin Pharmacol*. 2012 Apr;68(4):397-406. doi: 10.1007/s00228-011-1132-2. Epub 2011 Oct 18.PMID: 22006347 Clinical Trial.
301. Institutional Profile: Golden Helix Institute of Biomedical Research: interdisciplinary research and educational activities in pharmacogenomics and personalized medicine. Mitropoulos K, Innocenti F, van Schaik RH, Lezhava A, Tzimas G, Kollia P, Macek M Jr, Fortina P, Patrinos GP. *Pharmacogenomics*. 2012 Mar;13(4):387-92. doi: 10.2217/pgs.12.7.PMID: 22379996 Free PMC article.
302. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, Stricker BCh, van Schaik RH. *Pharmacogenet Genomics*. 2011 Dec;21(12):861-6. doi: 10.1097/FPC.0b013e32834c6edb.PMID: 21946898
303. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, Nulman I, Koren G, de Wildt SN. *J Heart Lung Transplant*. 2011 Dec;30(12):1352-9. doi: 10.1016/j.healun.2011.08.001. Epub 2011 Sep 17.PMID: 21930396 Free PMC article.
304. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, Parshuram C, Nulman I, Koren G. *Eur J Clin Pharmacol*. 2011 Dec;67(12):1231-41. doi: 10.1007/s00228-011-1083-7. Epub 2011 Jun 23.PMID: 21698374 Free PMC article.
305. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH. *Clin Chem*. 2011 Nov;57(11):1574-83. doi: 10.1373/clinchem.2011.165613. Epub 2011 Sep 8.PMID: 21903774 Free article. Clinical Trial.
306. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V. *Pharmacogenomics*. 2011 Oct;12(10):1383-96. doi: 10.2217/pgs.11.90. Epub 2011 Sep 8.PMID: 21902502
307. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, de Vos AI, van Alphen RJ, van der Holt B, Verweij J, Seynaeve C, Beijnen JH, Mathijssen RH. *J Clin Oncol*. 2011 Aug 20;29(24):3240-6. doi: 10.1200/JCO.2010.32.9839. Epub 2011 Jul 18.PMID: 21768449 Clinical Trial.
308. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. *Pharmacogenomics*. 2011 Aug;12(8):1137-46. doi: 10.2217/pgs.11.54. Epub 2011 Aug 10.PMID: 21830868
309. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Rakhmanina NY, Neely MN, Van Schaik RH, Gordish-Dressman HA, Williams KD, Soldin SJ, van den Anker JN. *Ther Drug Monit*. 2011 Aug;33(4):417-24. doi: 10.1097/FTD.0b013e318225384f.PMID: 21743379 Free PMC article.
310. CYP3A5 genotype is not related to the inpatient variability of tacrolimus clearance. Pashae N, Bouamar R, Hesselink DA, Roodnat JJ, van Schaik RH, Weimar W, van Gelder T. *Ther Drug Monit*. 2011 Jun;33(3):369-71. doi: 10.1097/FTD.0b013e31821a7aa3.PMID: 21566507
311. Pharmacogenomics and personalized medicine in clinical practice. Manolopoulos VG, Dechairo B, Huriez A, Kühn A, Llerena A, van Schaik RH, Yeo KT, Ragia G, Siest G. *Pharmacogenomics*. 2011 May;12(5):597-610. doi: 10.2217/pgs.11.14.PMID: 21619425
312. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. *J Urol*. 2011 May;185(5):1650-5. doi: 10.1016/j.juro.2010.12.032. Epub 2011 Mar 17.PMID: 21419439 Free PMC article. Clinical Trial.
313. Pharmacogenetics: from bench to byte--an update of guidelines. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deener VH, Guchelaar HJ. *Clin Pharmacol Ther*. 2011 May;89(5):662-73. doi: 10.1038/clpt.2011.34. Epub 2011 Mar 16.PMID: 21412232 Review.
314. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. Bouamar R, Hesselink DA, van Schaik RH, Weimar W, Macphee IA, de Fijter JW, van Gelder T. *Ther Drug Monit*. 2011 Apr;33(2):178-84. doi: 10.1097/FTD.0b013e31820feb8e.PMID: 21383650 Clinical Trial.
315. General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect. Obermann-Borst SA, Isaacs A, Younes Z, van Schaik RH, van der Heiden IP, van Duyn CM, Steegers EA, Steegers-Theunissen RP. *Am J Obstet Gynecol*. 2011 Mar;204(3):236.e1-8. doi: 10.1016/j.ajog.2010.10.911. Epub 2010 Dec 22.PMID: 21183151
316. OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. *Neurogenetics*. 2011 Feb;12(1):79-82. doi: 10.1007/s10048-010-0254-5. Epub 2010 Aug 1.PMID: 20680652 Free PMC article.
317. Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. Loos WJ, de Graan AJ, de Bruijn P, van Schaik RH, van Fessem MA, Lam MH, Mathijssen RH, Wiemer EA. *J Pharm Biomed Anal*. 2011 Jan 25;54(2):387-94. doi: 10.1016/j.jpba.2010.08.033. Epub 2010 Sep 21.PMID: 20926215
318. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK. *Pharmacogenomics*. 2011 Jan;12(1):113-24. doi: 10.2217/pgs.10.147.PMID: 21174626
319. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. Deenik W, van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkoppele GJ, van der Heiden IP, Sonneveld P, van Schaik RH, Cornelissen JJ. *Blood*. 2010 Dec 23;116(26):6144-5; author reply 6145-6. doi: 10.1182/blood-2010-07-296954.PMID: 21183698 Free article. No abstract available.

320. Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer--The Rotterdam Study. Siemes C, Visser LE, de Jong FH, Coebergh JW, Uitterlinden AG, Hofman A, Stricker BH, van Schaik RH. *Steroids*. 2010 Dec;75(12):1024-32. doi: 10.1016/j.steroids.2010.07.001. Epub 2010 Jul 31. PMID: 20621111
321. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. Bangma CH, van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman UH. *Eur J Cancer*. 2010 Nov;46(17):3109-19. doi: 10.1016/j.ejca.2010.09.031. PMID: 21047594
322. Nucleic acid reference materials (NARMs): definitions and issues. Payne DA, Mamotte CD, Gancberg D, Pazzagli M, van Schaik RH, Schimmel H, Rousseau F; IFCC Committee for Molecular Diagnostics (C-MD). *Clin Chem Lab Med*. 2010 Nov;48(11):1531-5. doi: 10.1515/CCLM.2010.313. Epub 2010 Oct 25. PMID: 20969510 Review.
323. CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Ruiters R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, van Noord C, Visser LE, Stricker BH. *Pharmacogenomics*. 2010 Oct;11(10):1367-75. doi: 10.2217/pgs.10.112. PMID: 21047200
324. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH. *Br J Cancer*. 2010 Sep 7;103(6):765-71. doi: 10.1038/sj.bjc.6605800. Epub 2010 Aug 10. PMID: 20700120 Free PMC article.
325. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, Danesi R. *EPMA J*. 2010 Sep;1(3):495-502. doi: 10.1007/s13167-010-0041-2. Epub 2010 Jul 25. PMID: 23199091 Free PMC article.
326. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. Gensburger O, Van Schaik RH, Picard N, Le Meur Y, Rousseau A, Woillard JB, Van Gelder T, Marquet P. *Pharmacogenet Genomics*. 2010 Sep;20(9):537-43. doi: 10.1097/FPC.0b013e32833d8cf5. PMID: 20679962 Free PMC article.
327. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. *Ther Drug Monit*. 2010 Jun;32(3):273-81. doi: 10.1097/FTD.0b013e3181dca14b. PMID: 20445485 Free PMC article.
328. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Jansen FH, van Schaik RH, Kurstjens J, Horninger W, Klocker H, Bektic J, Wildhagen MF, Roobol MJ, Bangma CH, Bartsch G. *Eur Urol*. 2010 Jun;57(6):921-7. doi: 10.1016/j.eururo.2010.02.003. Epub 2010 Feb 13. PMID: 20189711
329. The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. Schenk PW, van Vliet M, Mathot RA, van Gelder T, Vulto AG, van Fessem MA, Verploegh-Van Rij S, Lindemans J, Bruijn JA, van Schaik RH. *Pharmacogenomics J*. 2010 Jun;10(3):219-25. doi: 10.1038/tj.2009.50. Epub 2009 Nov 3. PMID: 19884907
330. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, Gelinck L, Kroon F, Wit FW, Van Schaik RH, Kuks PF, Burger DM. *AIDS*. 2010 May 15;24(8):1223-6. doi: 10.1097/QAD.0b013e3283389129. PMID: 20299957
331. CYP2D6*4, CYP3A5*3 and ABCB1 3435T polymorphisms and drug-related falls in elderly people. Blonk MI, van der Velde N, van den Bemt PM, van Schaik RH, van der Cammen TJ. *Pharm World Sci*. 2010 Feb;32(1):26-9. doi: 10.1007/s11096-009-9349-1. Epub 2009 Nov 28. PMID: 19946748
332. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Hartman A, van Schaik RH, van der Heiden IP, Broekhuis MJ, Meier M, den Boer ML, Pieters R. *Leuk Res*. 2010 Feb;34(2):154-9. doi: 10.1016/j.leukres.2009.04.027. Epub 2009 May 20. PMID: 19467705
333. Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. van der Bol JM, de Jong FA, van Schaik RH, Sparreboom A, van Fessem MA, van de Geijn FE, van Daele PL, Verweij J, Sleijfer S, Mathijssen RH. *Oncologist*. 2010;15(10):1063-72. doi: 10.1634/theoncologist.2010-0033. Epub 2010 Oct 7. PMID: 20930093 Free PMC article.
334. Genetic techniques for pharmacogenetic analyses. van der Straaten T, van Schaik RH. *Curr Pharm Des*. 2010;16(2):231-7. doi: 10.2174/138161210790112755. PMID: 20214624 Review.
335. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. *Pharmacogenet Genomics*. 2010 Jan;20(1):38-44. doi: 10.1097/FPC.0b013e328333bb11. PMID: 19898263
336. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. *Pharmacoevid Drug Saf*. 2010 Jan;19(1):75-81. doi: 10.1002/pds.1866. PMID: 19802823
337. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, VAN Schaik RH, Kuipers EJ, Kooiman JC, Geus WP. *Aliment Pharmacol Ther*. 2010 Jan;31(1):150-9. doi: 10.1111/j.1365-2036.2009.04150.x. PMID: 19785625 Clinical Trial.
338. Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. *Pharmacogenomics*. 2009 Nov;10(11):1743-51. doi: 10.2217/pgs.09.105. PMID: 19891551
339. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE. *Breast Cancer Res Treat*. 2009 Nov;118(1):125-30. doi: 10.1007/s10549-008-0272-2. Epub 2009 Feb 3. PMID: 19189212
340. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. Bliëk BJ, van Schaik RH, van der Heiden IP, Sayed-Tabatabaei FA, van Duijn CM, Steegers EA, Steegers-Theunissen RP; Eurocran Gene-Environment Interaction Group. *Am J Med Genet A*. 2009 Oct;149A(10):2088-92. doi: 10.1002/ajmg.a.33036. PMID: 19760622
341. A genome-wide association study of acenocoumarol maintenance dosage. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, Hofman A, De Smet PA, van Gelder T, Visser LE, Stricker BH. *Hum Mol Genet*. 2009 Oct 1;18(19):3758-68. doi: 10.1093/hmg/ddp309. Epub 2009 Jul 4. PMID: 19578179
342. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T. *Clin Pharmacol Ther*. 2009 Sep;86(3):319-27. doi: 10.1038/clpt.2009.83. Epub 2009 Jun 3. PMID: 19494809 Clinical Trial.

343. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. Kwadijk-de Gijssel S, Bijl MJ, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Ch Stricker BH. *Br J Clin Pharmacol*. 2009 Aug;68(2):221-5. doi: 10.1111/j.1365-2125.2009.03448.x.PMID: 19694742 Free PMC article.
344. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, Weimar W, Glander P, Essioux L, van Gelder T. *Pharmacogenet Genomics*. 2009 Aug;19(8):626-34. doi: 10.1097/FPC.0b013e32832f5f1b.PMID: 19617864
345. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. *Pharmacogenomics J*. 2009 Aug;9(4):242-7. doi: 10.1038/tpj.2009.15. Epub 2009 Apr 21.PMID: 19381165
346. MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patients. Kruit A, Tilanus-Linthorst MM, Boonstra JG, van Schaik RH, Grutters JC, van den Bosch JM, Ruven HJ. *Clin Biochem*. 2009 May;42(7-8):662-5. doi: 10.1016/j.clinbiochem.2008.11.020. Epub 2008 Dec 24.PMID: 19121298
347. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Siemes C, Eijgelsheim M, Dieleman JP, van Schaik RH, Uitterlinden AG, van Duijn CM, Hofman A, Coebergh JW, Stricker BH, Visser LE. *Neth J Med*. 2009 Apr;67(4):134-41.PMID: 19581657 Free article.
348. Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly. Bijl MJ, Luijendijk HJ, van den Berg JF, Visser LE, van Schaik RH, Hofman A, Vulto AG, van Gelder T, Tiemeier H, Stricker BH. *Pharmacogenomics*. 2009 Apr;10(4):541-7. doi: 10.2217/pgs.09.9.PMID: 19374513
349. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Teichert M, van Schaik RH, Hofman A, Uitterlinden AG, de Smet PA, Stricker BH, Visser LE. *Clin Pharmacol Ther*. 2009 Apr;85(4):379-86. doi: 10.1038/clpt.2008.294. Epub 2009 Feb 18.PMID: 19225451
350. Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. van Luin M, Brouwer AM, van der Ven A, de Lange W, van Schaik RH, Burger DM. *AIDS*. 2009 Mar 27;23(6):742-4. doi: 10.1097/QAD.0b013e32832914a3.PMID: 19279450 No abstract available.
351. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. *Diabetes*. 2009 Mar;58(3):745-9. doi: 10.2337/db08-1028. Epub 2009 Feb 19.PMID: 19228809 Free PMC article.
352. Pharmacogenetic pathway analysis of docetaxel elimination. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. *Clin Pharmacol Ther*. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28.PMID: 18509327 Free PMC article.
353. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Bijl MJ, Visser LE, van Schaik RH, Kors JA, Witteman JC, Hofman A, Vulto AG, van Gelder T, Stricker BH. *Clin Pharmacol Ther*. 2009 Jan;85(1):45-50. doi: 10.1038/clpt.2008.172. Epub 2008 Sep 10.PMID: 18784654
354. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Jansen FH, Roobol M, Bangma CH, van Schaik RH. *Clin Chem*. 2008 Dec;54(12):1999-2006. doi: 10.1373/clinchem.2007.102699. Epub 2008 Oct 16.PMID: 18927249
355. AcylIMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. van Agteren M, Armstrong VW, van Schaik RH, de Fijter H, Hartmann A, Zeier M, Budde K, Kuypers D, Pisarski P, Le Meur Y, van der Werf M, Mamelok RD, Oellerich M, van Gelder T. *Ther Drug Monit*. 2008 Aug;30(4):439-44. doi: 10.1097/FTD.0b013e318180c709.PMID: 18641546 Clinical Trial.
356. A drug transporter for all ages? ABCB1 and the developmental pharmacogenetics of cyclosporine. Hesselink DA, van Schaik RH, Nauta J, van Gelder T. *Pharmacogenomics*. 2008 Jun;9(6):783-9. doi: 10.2217/14622416.9.6.783.PMID: 18518855
357. CYP450 pharmacogenetics for personalizing cancer therapy. van Schaik RH. *Drug Resist Updat*. 2008 Jun;11(3):77-98. doi: 10.1016/j.drug.2008.03.002. Epub 2008 May 19.PMID: 18486526 Review.
358. Postmenstrual age and CYP2D6 polymorphisms determine tramadol o-demethylation in critically ill neonates and infants. Allegaert K, van Schaik RH, Vermeersch S, Verbesselt R, Cossey V, Vanhole C, van Fessem M, de Hoon J, van den Anker JN. *Pediatr Res*. 2008 Jun;63(6):674-9. doi: 10.1203/PDR.0b013e31816ff712.PMID: 18317231 Clinical Trial.
359. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Schenk PW, van Fessem MA, Verploegh-Van Rij S, Mathot RA, van Gelder T, Vulto AG, van Vliet M, Lindemans J, Bruijn JA, van Schaik RH. *Mol Psychiatry*. 2008 Jun;13(6):597-605. doi: 10.1038/sj.mp.4002057. Epub 2007 Jul 31.PMID: 17667959
360. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ, Geus WP. *Br J Clin Pharmacol*. 2008 May;65(5):752-60. doi: 10.1111/j.1365-2125.2007.03094.x. Epub 2008 Jan 30.PMID: 18241283 Free PMC article. Clinical Trial.
361. Subclinical hypocalcaemia in captive Asian elephants (*Elephas maximus*). van der Kolk JH, van Leeuwen JP, van den Belt AJ, van Schaik RH, Schaftenaar W. *Vet Rec*. 2008 Apr 12;162(15):475-9. doi: 10.1136/vr.162.15.475.PMID: 18408195
362. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes. van Schaik RH. *EJIFCC*. 2008 Apr 3;19(1):42-7. eCollection 2008 Apr.PMID: 27683289 Free PMC article. No abstract available.
363. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, Budde K, Kuypers DR, Pisarski P, Le Meur Y, Mamelok RD, van Gelder T. *Pharmacogenet Genomics*. 2008 Apr;18(4):339-48. doi: 10.1097/FPC.0b013e3282f75f88.PMID: 18334918 Clinical Trial.
364. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH. *Pharmacogenet Genomics*. 2008 Apr;18(4):299-305. doi: 10.1097/FPC.0b013e3282f70458.PMID: 18334914
365. Covariates of tramadol disposition in the first months of life. Allegaert K, van den Anker JN, de Hoon JN, van Schaik RH, Debeer A, Tibboel D, Naulaers G, Anderson BJ. *Br J Anaesth*. 2008 Apr;100(4):525-32. doi: 10.1093/bja/aen019. Epub 2008 Feb 26.PMID: 18303070 Free article.

366. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study. Teichert M, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, De Smet PA, Witteman JC, Stricker BH. *Arterioscler Thromb Vasc Biol.* 2008 Apr;28(4):771-6. doi: 10.1161/ATVBAHA.107.159913. Epub 2008 Jan 24. PMID: 18218987
367. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH. *Br J Clin Pharmacol.* 2008 Apr;65(4):558-64. doi: 10.1111/j.1365-2125.2007.03052.x. Epub 2007 Dec 7. PMID: 18070221 Free PMC article.
368. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. *Am J Hematol.* 2008 Mar;83(3):200-2. doi: 10.1002/ajh.21051. PMID: 17724700 Free article.
369. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. *Clin Pharmacol Ther.* 2008 Feb;83(2):288-92. doi: 10.1038/sj.cpt.6100273. Epub 2007 Jun 27. PMID: 17597710
370. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. Levin MD, den Hollander JG, van der Holt B, Rijnders BJ, van Vliet M, Sonneveld P, van Schaik RH. *J Antimicrob Chemother.* 2007 Nov;60(5):1104-7. doi: 10.1093/jac/dkm330. Epub 2007 Sep 7. PMID: 17827141
371. Tubular and interstitial nephrocalcinosis. Kummeling MT, de Jong BW, Laffeber C, Kok DJ, Verhagen PC, van Leenders GJ, van Schaik RH, van Woerden CS, Verhulst A, Verkoelen CF. *J Urol.* 2007 Sep;178(3 Pt 1):1097-103. doi: 10.1016/j.juro.2007.05.008. Epub 2007 Jul 20. PMID: 17644134
372. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Engels FK, Loos WJ, Mathot RA, van Schaik RH, Verweij J. *Cancer Chemother Pharmacol.* 2007 Sep;60(4):569-79. doi: 10.1007/s00280-006-0412-5. Epub 2007 Jan 26. PMID: 17256132 Free article.
373. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Krekels EH, van den Anker JN, Baiardi P, Cella M, Cheng KY, Gibb DM, Green H, Iolascon A, Jacqz-Aigrain EM, Knibbe CA, Santen GW, van Schaik RH, Tibboel D, Della Pasqua OE. *Expert Opin Pharmacother.* 2007 Aug;8(12):1787-99. doi: 10.1517/14656566.8.12.1787. PMID: 17696784 Review.
374. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. van der Bol JM, Mathijssen RH, Loos WJ, Friberg LE, van Schaik RH, de Jonge MJ, Planting AS, Verweij J, Sparreboom A, de Jong FA. *J Clin Oncol.* 2007 Jul 1;25(19):2719-26. doi: 10.1200/JCO.2006.09.6115. Epub 2007 Jun 11. PMID: 17563393 Clinical Trial.
375. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH. *Pharmacogenet Genomics.* 2007 Jul;17(7):473-9. doi: 10.1097/01.fpc.0000236335.57046.c8. PMID: 17558303
376. Effects of the renin-angiotensin system genes and salt sensitivity genes on blood pressure and atherosclerosis in the total population and patients with type 2 diabetes. Yazdanpanah M, Aulchenko YS, Hofman A, Janssen JA, Sayed-Tabatabaei FA, van Schaik RH, Klungel OH, Stricker BH, Pols HA, Witteman JC, Lamberts SW, Oostra BA, van Duijn CM. *Diabetes.* 2007 Jul;56(7):1905-12. doi: 10.2337/db06-1127. Epub 2007 Apr 19. PMID: 17446534
377. C-kit Asp-816-Val mutation analysis in patients with mastocytosis. Verzijl A, Heide R, Oranje AP, van Schaik RH. *Dermatology.* 2007;214(1):15-20. doi: 10.1159/000096907. PMID: 17191042
378. A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Lee SJ, van der Heiden IP, Goldstein JA, van Schaik RH. *Drug Metab Dispos.* 2007 Jan;35(1):67-71. doi: 10.1124/dmd.106.012310. Epub 2006 Oct 11. PMID: 17035598 Free PMC article.
379. Cardiac aldosterone in subjects with hypertrophic cardiomyopathy. Chai W, Hoedemaekers Y, van Schaik RH, van Fessem M, Garrelds IM, Saris JJ, Dooijes D, ten Cate FJ, Kofflard MM, Danser AH. *J Renin Angiotensin Aldosterone Syst.* 2006 Dec;7(4):225-30. doi: 10.3317/jraas.2006.042. PMID: 17318792 Free article.
380. Pharmacokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Peeters MY, Prins SA, Knibbe CA, Dejongh J, Mathôt RA, Warris C, van Schaik RH, Tibboel D, Danhof M. *Anesthesiology.* 2006 Dec;105(6):1135-46. doi: 10.1097/0000542-200612000-00013. PMID: 17122576 Clinical Trial.
381. Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms. Hofland J, Timmerman MA, de Herder WW, van Schaik RH, de Krijger RR, de Jong FH. *Clin Endocrinol (Oxf).* 2006 Dec;65(6):792-9. doi: 10.1111/j.1365-2265.2006.02668.x. PMID: 17121532
382. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, Löwenberg B, Sonneveld P. *Clin Pharmacol Ther.* 2006 Nov;80(5):427-39. doi: 10.1016/j.cpt.2006.07.005. PMID: 17112800
383. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP, Stricker BH. *Clin Pharmacol Ther.* 2006 Oct;80(4):367-74. doi: 10.1016/j.cpt.2006.07.003. PMID: 17015054
384. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. de Jong FA, Kehr DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ. *Oncologist.* 2006 Sep;11(8):944-54. doi: 10.1634/theoncologist.11-8-944. PMID: 16951398 Free article. Clinical Trial.
385. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K. *Clin Pharmacol Ther.* 2006 Aug;80(2):192-201. doi: 10.1016/j.cpt.2006.05.003. PMID: 16890580
386. Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. de Bont JM, den Boer ML, Reddingius RE, Jansen J, Passier M, van Schaik RH, Kros JM, Sillevis Smitt PA, Luijckx TH, Pieters R. *Clin Chem.* 2006 Aug;52(8):1501-9. doi: 10.1373/clinchem.2006.069294. Epub 2006 Jun 8. PMID: 16762995
387. Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J. *Cancer Biol Ther.* 2006 Jul;5(7):833-9. doi: 10.4161/cbt.5.7.2839. Epub 2006 Jul 22. PMID: 16775418 Free article. Clinical Trial.
388. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. van der Padt A, van Schaik RH, Sonneveld P. *Neth J Med.* 2006 May;64(5):160-2. PMID: 16702617 Free article.

389. Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Peeters MY, Prins SA, Knibbe CA, DeJongh J, van Schaik RH, van Dijk M, van der Heiden IP, Tibboel D, Danhof M. *Anesthesiology*. 2006 Mar;104(3):466-74. doi: 10.1097/00000542-200603000-00013.PMID: 16508393
390. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Mathijssen RH, van Schaik RH. *Eur J Cancer*. 2006 Jan;42(2):141-8. doi: 10.1016/j.ejca.2005.08.035. Epub 2005 Dec 1.PMID: 16325399 Review.
391. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. van Schaik RH. *Invest New Drugs*. 2005 Dec;23(6):513-22. doi: 10.1007/s10637-005-4019-1.PMID: 16267627 Review.
392. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. *Clin Cancer Res*. 2005 Oct 15;11(20):7398-404. doi: 10.1158/1078-0432.CCR-05-0520.PMID: 16243813 Clinical Trial.
393. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. Smit P, van Schaik RH, van der Werf M, van den Beld AW, Koper JW, Lindemans J, Pols HA, Brinkmann AO, de Jong FH, Lamberts SW. *J Clin Endocrinol Metab*. 2005 Sep;90(9):5313-6. doi: 10.1210/jc.2005-0307. Epub 2005 Jun 28.PMID: 15985487
394. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Hesselink DA, van Gelder T, van Schaik RH. *Pharmacogenomics*. 2005 Jun;6(4):323-37. doi: 10.1517/14622416.6.4.323.PMID: 16004552 Review.
395. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. *Clin Pharmacol Ther*. 2005 Jun;77(6):479-85. doi: 10.1016/j.cpt.2005.02.009.PMID: 15961979
396. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. *Clin Cancer Res*. 2005 Feb 15;11(4):1504-11. doi: 10.1158/1078-0432.CCR-04-1758.PMID: 15746053 Free article. Clinical Trial.
397. Factors affecting cytochrome P-450 3A activity in cancer patients. Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ, Schenk PW, Charles KA, Clarke SJ, Carducci MA, McGuire WP, Dawkins F, Gelderblom H, Verweij J, Sparreboom A. *Clin Cancer Res*. 2004 Dec 15;10(24):8341-50. doi: 10.1158/1078-0432.CCR-04-1371.PMID: 15623611
398. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Hesselink DA, van Gelder T, van Schaik RH, Balk AH, van der Heiden IP, van Dam T, van der Werf M, Weimar W, Mathot RA. *Clin Pharmacol Ther*. 2004 Dec;76(6):545-56. doi: 10.1016/j.cpt.2004.08.022.PMID: 15592326
399. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A. *J Natl Cancer Inst*. 2004 Nov 3;96(21):1585-92. doi: 10.1093/jnci/djh298.PMID: 15523087
400. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH. *J Clin Endocrinol Metab*. 2004 Sep;89(9):4391-6. doi: 10.1210/jc.2004-0232.PMID: 15356036
401. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. *Thromb Haemost*. 2004 Jul;92(1):61-6. doi: 10.1160/TH03-12-0741.PMID: 15213846
402. Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. van Schaik RH. *Ther Drug Monit*. 2004 Apr;26(2):236-40. doi: 10.1097/00007691-200404000-00027.PMID: 15228172 Review.
403. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. *Pharmacogenetics*. 2004 Jan;14(1):27-33. doi: 10.1097/00008571-200401000-00003.PMID: 15128048
404. Sequencing: not always the "gold standard". van der Heiden IP, van der Werf M, Lindemans J, van Schaik RH. *Clin Chem*. 2004 Jan;50(1):248-9. doi: 10.1373/clinchem.2003.024604.PMID: 14709666 No abstract available.
405. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Geogor PJ, Lindemans J, Weimar W, van Gelder T. *Clin Pharmacol Ther*. 2003 Sep;74(3):245-54. doi: 10.1016/S0009-9236(03)00168-1.PMID: 12966368
406. CYP3A5 variant allele frequencies in Dutch Caucasians. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. *Clin Chem*. 2002 Oct;48(10):1668-71.PMID: 12324482
407. The CYP3A4*3 allele: is it really rare? van Schaik RH, de Wildt SN, Brossens R, van Fessem M, van den Anker JN, Lindemans J. *Clin Chem*. 2001 Jun;47(6):1104-6.PMID: 11375299 No abstract available.
408. Detection limit, cut-off and specificity of an improved rapid assay for cardiac troponin T. Baum H, Bertsch T, Bohner J, von Pap KW, Hoff T, Wilke B, Katz N, Luthe H, Luz H, Nagel D, Niederhauser C, van Schaik RH, Aschenneller C, Schul I, Zerback R. *Clin Lab*. 2001;47(11-12):549-54.PMID: 11759956
409. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. *Clin Chem*. 2000 Nov;46(11):1834-6.PMID: 11067821 No abstract available.

Projects

- 2025 ZONMW GGG: P4Care – DNA-passport in first line care
- 2019 ZONMW: COIN – Clinical Implementation of cfDNA (PI: D. van den Broek)
- 2017 Nierstichting: Early and detection of kidney transplant rejection (PI K. Boer)
- 2016 MRACE grant: Cell free DNA for monitoring heart transplant rejection (PI)
- 2016 NOYONS grant: Cell free DNA for monitoring heart transplant rejection (PI)
- 2016 ZONMW grant Antidepressants in children (PI: Birgit Koch)
- 2011 MRACE grant: 4OH cholesterol as a CYP3A4 endogenous markers (PI)

2010 Dutch Cancer Society (KWF): Pharmacogenetics of taxanes (PI)
 2010 ZONMW – Priority Medicines Children Pharmacokinetic, efficacy and long term effects of Metformin in adolescents with type 2 diabetes mellitus and/or obesity resistance. (PI: MMJ van der Vorst).
 2010 ZONMW –Priority Medicines Elderly. Utilisation, effectiveness, and adverse effects of antidepressants in the elderly (PI: LE Visser).
 2009 EU- FP7 grant NeoOpioid: Less pain in children (PI: H Lagercranz)
 2009 ZONMW: Opioidrotation for reducing pain in cancer patients (PI: C. van der Rijt).
 2008 Pain Grant: Pharmacogenetics of anti-analgesic (PI D. Burger).
 2005 MRACE grant: Pharmacogenetics and anti-HIV drugs (PI)
 2005 EU-FP6 Identification of new markers for Prostate Cancer (PI C. Bangma)
 2004 Roche Pharma FDCC grant: Pharmacogenetics of transplantation (PI)
 1999 MRACE Top-Down grant: Pharmacogenetics of tamoxifen, antidepressives and chemotherapeutics (PI)
 1998 Dutch Society for Scientific Research NWO (travelgrant)

Memberships

2020 - present International Pharmacogenetics Research Network (PGRN) (founding member)
 2020 - present PharmVar - consortium (member)
 2020 - present Association for Molecular Pathology (AMP) – PGx working group (member)
 2018 – present SKML committee Molecular Biology (chair)
 2018 – 2024 NHS / Genomics England Pharmacogenetics Working Group
 2018 – 2024 IFCC workinggroup cell-free DNA (chair)
 2016 - present European Society Pharmacogenomics & Personalized Therapy (ESPT) (Founder/President/Board member)
 2016 - present European Pharmacogenetics Implementation Consortium (Eu-PIC) (Chair)
 2015 - present Genomic Medicine Alliance (member)
 2013 - present Clinical Pharmacogenetics Implementation Consortium (CPIC) (member)
 2013 - present IUPHAR Pharmacogenetics Committee (member)
 2013 - 2017 EFLM working group Personalized Medicine
 2012 - 2016 AACC Personalized Medicine Division (founding member, division officer)
 2010 - 2022 European Medicine Agency (EMA) Working Group Pharmacogenetics (advisor)
 2008 - 2016 IFCC Task Force Pharmacogenetics (chair)
 2004 - 2008 IFCC Committee Molecular Biology Diagnostics (member)
 2008 - 2016 IATDMCT Committee Pharmacogenetics (chair)
 2008 - 2012 EUSPM (European Society for Personalized Medicine) (treasurer)
 2006 - 2016 ENPR (European Network Pharmacogenetic Research) (steering committee)

NATIONAL

2015 - present Dutch Clinical Pharmacogenetics Network (chair) (www.pgx-net.nl)
 2013 - present NVKC/NVZA/KNMP Joint working group Clinical Chemistry/Pharmacology (chair)
 2006 - 2013 NVKC Scientific Committee Clinical Chemistry (chair)
 2006 - present NVKC/CMBD (Committee Molecular Biology Diagnostics) (chair)
 2007 - present Dutch Pharmacogenetics Working Group (DPWG) (member)

Other Relevant Information

Awards :

2010: AACC Scientific Outstanding Research Award (AACC Annual Meeting, Anaheim)
 2009: AACC Outstanding Speaker Award
 2008 IFCC Molecular Diagnostic Expert Center Pharmacogenetics
 2008: NVKC Scientific Award (Netherlands Society for Clinical Chemistry)
 2001: NVKC Ortho_Clinical Diagnostics award for Clinical Chemistry